[
  {
    "question": "A 68-year-old male with a history of hypertension and type 2 diabetes presents with a 3-day history of cough, fever, and shortness of breath. He is diagnosed with community-acquired pneumonia (CAP). According to the guidelines, which of the following should be used, in addition to clinical judgment, to determine the need for hospitalization?",
    "context": "urea level, respiratory rate, blood pressure, and age &gt;=65) (conditional recommendation, low quality of evidence), to determine the need for hospitalization in adults diagnosed with CAP.\nprompt assessment for a pathogen resistant to the current therapy and/or complications of pneumonia (e.g., empyema or lung abscess) or for an alternative source of infection and/or inflammatory response (208, 209). When assessment of clinical stability has been introduced into clinical practice,\nIn addition to clinical judgement, we recommend that clinicians use a validated clinical prediction rule for prognosis, preferentially the Pneumonia Severity Index (PSI) (strong recommendation, moderate quality of evidence) over the CURB-65 (tool based on confusion, urea level, respiratory rate,\nClinical severity is not the only consideration in determining the need for hospital admission (49, 50). Some patients have medical and/or psychosocial contraindications to outpatient therapy, such as inability to maintain oral intake, history of substance abuse, cognitive impairment, severe\nThis document provides evidence-based clinical practice guidelines on the management of adult patients with community-acquired pneumonia.\nThe panel formulated and provided the rationale for recommendations on selected diagnostic and treatment strategies for adult patients with community-acquired pneumonia.",
    "ground_truth_context": "In addition to clinical judgement, we recommend that clinicians use a validated clinical prediction rule for prognosis, preferentially the Pneumonia Severity Index (PSI) (strong recommendation, moderate quality of evidence) over the CURB-65 (tool based on confusion, urea level, respiratory rate, blood pressure, and age >65) (conditional recommendation, low quality of evidence), to determine the need for hospitalization in adults diagnosed with CAP. [1]",
    "model_answer": "B",
    "model_answer_idx": 2,
    "correct_answer_text": "Pneumonia Severity Index (PSI) preferentially over CURB-65",
    "correct_answer_idx": 1,
    "model_reasoning": "According to the guidelines for managing community-acquired pneumonia (CAP), clinicians are advised to use a validated clinical prediction rule for prognosis, specifically recommending the Pneumonia Severity Index (PSI) preferentially over the CURB-65 score. This recommendation is based on a strong endorsement and moderate quality of evidence. The PSI is designed to help assess the severity of pneumonia and determine the need for hospitalization, while CURB-65 is considered a less preferred option. Other options, such as serum procalcitonin levels and influenza virus testing, are not intended for assessing the need for hospitalization but rather for guiding antibiotic initiation and identifying viral infections, respectively. Therefore, the most appropriate choice in this context is option B, which aligns with the guidelines provided.",
    "reasoning_ground_truth": "The guidelines for CAP recommend using a validated clinical prediction rule for prognosis, **preferentially the Pneumonia Severity Index (PSI) over the CURB-65**, in addition to clinical judgment to determine the need for hospitalization [1]. Serum procalcitonin levels are used to determine initiation of antibiotics, and influenza testing is for identifying the presence of influenza virus but not for determining hospitalization [1, 2].",
    "is_correct": false
  },
  {
    "question": "A 55-year-old female with a history of chronic kidney disease (CKD) and hypertension presents for a routine follow-up. Her eGFRcr is 40 mL/min/1.73 m2. Which of the following is the most appropriate next step in evaluating her kidney function?",
    "context": "In this section, we describe the overall approach for the evaluation of GFR. As in the previous KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, the first method to evaluate GFR should be eGFRcr. If necessary for greater accuracy, the approach then\nPractice Point 1.1.1.1: Test people at risk for and with chronic kidney disease (CKD) using both urine albumin measurement and assessment of glomerular filtration rate (GFR).\nPractice Point 1.1.1.1: Test people at risk for and with chronic kidney disease (CKD) using both urine albumin measurement and assessment of glomerular filtration rate (GFR).\nPractice Guideline for the Evaluation and Management of Chronic Kidney Disease1 for GFR estimation in adults, there have been 3 main sources of validated equations: those developed by the CKD-EPI, those developed by EKFC, and modifications of each for use in specific regions (Table 14\nPractice Point 2.1.3: For people with CKD, a change in eGFR of >20% on a subsequent test exceeds the expected variability and warrants evaluation.\nFor people with CKD, a change in eGFR of >20% on a subsequent test exceeds the expected variability and warrants evaluation.\nSome authors have suggested that the GFR threshold for CKD of 60 ml/min per 1.73 m2 should be raised to 75 ml/min per 1.73 m2 for younger adults and lowered to 45 ml/min per 1.73 m2 for older adults. In younger adults, the purpose of a higher GFR threshold reflects the longer risk horizon for\nPractice Point 2.2.1: A 5-year kidney failure risk of 3%\u20135% can be used to determine need for nephrology referral in addition to criteria based on eGFR or urine ACR, and other clinical considerations.\nPractice Point 1.1.1.2: Following incidental detection of elevated urinary albumin-to-creatinine ratio (ACR), hematuria, or low estimated GFR (eGFR), repeat tests to confirm presence of CKD.\nFollowing incidental detection of elevated urinary albumin-to-creatinine ratio (ACR), hematuria, or low estimated GFR (eGFR), repeat tests to confirm presence of CKD.",
    "ground_truth_context": "The initial test for the evaluation of GFR is creatinine-based estimated GFR (eGFRcr), which will be available for most people because creatinine is measured routinely as part of the basic metabolic panel. If eGFRcr is expected to be inaccurate, or if a more accurate assessment of GFR is needed for clinical decision-making, such as diagnosis or staging of chronic kidney disease or drug dosing, then, if available, cystatin C should be measured, and creatinine and cystatin C\u2013based estimated GFR (eGFRcr-cys) should be estimated. [3] eGFRcr-cys provides the most accurate estimate and is recommended as the primary supportive test for people in whom there are concerns about eGFRcr accuracy [4] ",
    "model_answer": "A",
    "model_answer_idx": 1,
    "correct_answer_text": "Measure cystatin C to calculate eGFRcr-cys",
    "correct_answer_idx": 0,
    "model_reasoning": "According to the guidelines for evaluating glomerular filtration rate (GFR), the initial test is the creatinine-based estimated GFR (eGFRcr). In cases where the eGFRcr is thought to be inaccurate or when a more precise assessment of GFR is required for clinical decision-making, measuring cystatin C is recommended. This allows for the calculation of eGFRcr-cys, which provides a more accurate estimate of kidney function. Given that the patient has chronic kidney disease (CKD) and an eGFRcr of 40 mL/min/1.73 m\u00b2, it is prudent to measure cystatin C to ensure the accuracy of the GFR assessment before considering further steps. Therefore, option A is the most appropriate next step in evaluating her kidney function.",
    "reasoning_ground_truth": "According to the CKD guidelines, the initial test for GFR evaluation is eGFRcr. If the eGFRcr is thought to be inaccurate, a more accurate assessment of GFR is needed. In such cases, cystatin C should be measured to estimate eGFRcr-cys.  If eGFRcr-cys is inaccurate, then mGFR can be considered [3, 4].",
    "is_correct": false
  },
  {
    "question": "A 70-year-old male with a history of a recent acute coronary syndrome (ACS) is currently on dual antiplatelet therapy (DAPT). He is now 18 months post-ACS and has had no recurrent events. What is the recommended approach for his DAPT?",
    "context": "high-risk features to either DAPT (with ticagrelor 60 mg or 90 mg twice daily) or continued aspirin monotherapy (28). After a mean of 33 months of therapy, DAPT, when compared with aspirin monotherapy, resulted in a 1.2% to 1.3% absolute reduction in the primary composite endpoint of cardiovascular\nRandomized to either DAPT (with ticagrelor 60 mg or 90 mg twice daily) or continued aspirin monotherapy, a mean of 33 months of DAPT led to a 1.2% to 1.3% absolute reduction in ischemic events and a 1.2% to 1.5% increase in major bleeding (28). In subgroup analysis, the greatest reduction in\n|IIa|B-R|In patients with ACS treated with DAPT after coronary stent implantation, who are not at high risk for bleeding complications and who do not have a history of stroke or TIA, it is reasonable to choose prasugrel over clopidogrel for maintenance P2Y12 inhibitor therapy (54,55).|\nin patients in whom P2Y12 inhibitor therapy had been discontinued >1 year before enrollment in the study (42). Decisions about treatment with and duration of DAPT in patients with ACS require a thoughtful assessment of the benefit/risk ratio, integration of study data, and consideration of patient\nThe scope of this focused update is limited to addressing recommendations on duration of dual antiplatelet therapy (DAPT) (aspirin plus a P2Y12 inhibitor) in patients with coronary artery disease (CAD). Recommendations considered are those in 6 guidelines: \u201c2011 ACCF/AHA/SCAI Guideline for\nindividual basis and should integrate clinical judgment, assessment of the benefit/risk ratio, and patient preference. Aspirin therapy is almost always continued indefinitely in patients with CAD, and recommendations on duration of DAPT should be taken to mean the recommended duration of P2Y12\n|IIb|ASR|In patients with ACS treated with coronary stent implantation who have tolerated DAPT without bleeding complication and who are not at high bleeding risk (e.g., prior bleeding on DAPT, coagulopathy, oral anticoagulant use) continuation of DAPT for longer than 12 months may be reasonable\nGuidelines from the cardiology community provide recommendations for the use of dual antiplatelet therapy for a period after acute coronary syndrome or percutaneous coronary intervention. These guidelines recommend to apply the same diagnostic and therapeutic strategies in people with CKD.663 CKD\n|COR|LOE|RECOMMENDATIONS|\n|---|---|---|\n|I|B-R|In patients with ACS who are managed with medical therapy alone (without revascularization or fibrinolytic therapy) and treated with DAPT, P2Y12 inhibitor therapy (clopidogrel or ticagrelor) should be continued for at least 12 months (52,71,140,141).|\n|I|C-EO|In patients treated with DAPT after coronary stent implantation who must undergo surgical procedures that mandate the discontinuation of P2Y12 inhibitor therapy, it is recommended that aspirin be continued if possible and the P2Y12 platelet receptor inhibitor be restarted as soon as",
    "ground_truth_context": "patients with a history of acute coronary syndrome (ACS) >1 year prior who have since remained free of recurrent ACS are considered to have transitioned to stable ischemic heart disease (SIHD) and are addressed in the section on SIHD.  This focused update is designed to function both as a standalone document and to serve as an update to the relevant sections on duration of DAPT in the 6 clinical practice guidelines, replacing relevant text, figures, and recommendations. [5]",
    "model_answer": "B",
    "model_answer_idx": 2,
    "correct_answer_text": "Transition to single antiplatelet therapy.",
    "correct_answer_idx": 1,
    "model_reasoning": "According to the guidelines referenced in the context, patients who have a history of acute coronary syndrome (ACS) and are more than one year post-event, while remaining free of recurrent ACS, are considered to have transitioned to stable ischemic heart disease (SIHD). In such cases, the recommended approach is to transition from dual antiplatelet therapy (DAPT) to single antiplatelet therapy. This is based on the understanding that after one year, the risks and benefits of continuing DAPT versus transitioning to single therapy favor the latter for patients who have not experienced any recurrent events. Therefore, for the 70-year-old male in the scenario, the appropriate recommendation is to transition to single antiplatelet therapy (option B).",
    "reasoning_ground_truth": "According to the guidelines, patients with a history of ACS >1 year prior who have remained free of recurrent ACS are considered to have transitioned to stable ischemic heart disease (SIHD). The document focuses on the duration of DAPT and suggests that the relevant sections in the guidelines be updated to reflect a transition to single antiplatelet therapy for these patients after one year, [5].",
    "is_correct": false
  },
  {
    "question": "A 35-year-old female presents with a 5-day history of nasal congestion, facial pain, and purulent nasal discharge. She reports no improvement with over-the-counter decongestants. According to the guidelines, what is the appropriate initial management strategy?",
    "context": "Oral decongestants may provide symptomatic relief and should be considered barring any medical contraindications, such as hypertension or anxiety. The use of topical decongestant is likely to be palliative, but continuous duration of use should not exceed 3 to 5 days, as recommended by the\nAdjunctive treatments for rhinosinusitis that may aid in symptomatic relief include analgesics, decongestants (\u03b1-adrenergic), corticosteroids, saline irrigation, and mucolytics. None of these products has been specifically approved by the FDA for use in acute rhinosinusitis (as of March 2014), and\nagents, nasal saline, decongestants, antihistamines, mucolytics, cough suppressants, and topical or oral corticosteroids\u2014may be used alone or in varying combinations for symptom relief.\ndocumentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. The update group made recommendations that clinicians (1) should either offer watchful waiting (without antibiotics) or prescribe initial antibiotic therapy for\nClinicians may recommend analgesics, topical intranasal steroids, and/or nasal saline irrigation for symptomatic relief of VRS. Option based on randomized controlled trials with limitations and cohort studies with an unclear balance of benefit and harm that varies by patient.\nnasal drainage accompanied by nasal obstruction, facial pain-pressure-fullness, or both) persist without\nnot be used more than 3 to 5 consecutive days without a prolonged intervening drug-free period due to their propensity to cause rebound congestion and rhinitis medicamentosa.87\nDecongestants may help you breathe easier and can be taken as a nasal spray (for no more than 3 days in a row to avoid worsening congestion) or by mouth.|\n5 days, as recommended by the manufacturers, to avoid rebound congestion and rhinitis medicamentosa. Clinical experience suggests oral antihistamines may provide symptomatic relief of excessive secretions and sneezing, although there are no clinical studies supporting the use of antihistamines in",
    "ground_truth_context": "Extension of watchful waiting (without antibiotic therapy) as an initial management strategy to all patients with uncomplicated acute bacterial rhi-nosinusitis (ABRS) regardless of severity, not just patients with \u201cmild\u201d illness (prior guideline) [6]. The purpose of this statement is to encourage consideration of supportive therapies that may improve quality of life for indi-viduals with viral rhinosinusitis (VRS) and to avoid unneces-sary prescribing of antibiotics for viral disease. [7]",
    "model_answer": "B",
    "model_answer_idx": 2,
    "correct_answer_text": "Watchful waiting without antibiotics",
    "correct_answer_idx": 1,
    "model_reasoning": "According to the guidelines for managing uncomplicated acute bacterial rhinosinusitis (ABRS), the appropriate initial management strategy is to adopt a \"watchful waiting\" approach without the immediate use of antibiotics. This recommendation applies regardless of the severity of the symptoms. The rationale behind this strategy is to avoid unnecessary antibiotic prescriptions, especially since many cases of rhinosinusitis are viral in nature and do not require antibiotic treatment. Supportive therapies can be considered to alleviate symptoms, but the focus is on monitoring the patient's condition before deciding on further interventions. Therefore, in this case, the correct answer is B: Watchful waiting without antibiotics.",
    "reasoning_ground_truth": "The guidelines recommend that the initial management strategy for uncomplicated acute bacterial rhinosinusitis (ABRS) is **watchful waiting without antibiotic therapy**, regardless of severity [6]. Supportive therapies for symptom relief can also be considered [7].",
    "is_correct": false
  },
  {
    "question": "A 40-year-old male presents to the emergency department with a witnessed seizure lasting 7 minutes. He has no known history of epilepsy. According to the guidelines, what is the recommended initial therapy?",
    "context": "The second-therapy phase should begin when the seizure duration reaches 20 minutes and should conclude by the 40-minute mark when response (or lack of response) to the second therapy should be apparent. Reasonable options include fosphenytoin (level U), valproic acid (level B, one class II study)\nor longer, or two or more GTC seizures without full recovery of consciousness. A treatment was successful if the status epilepticus stopped within 20 minutes after infusion started with no recurrence prior to 60 minutes. Overall, 570 patients were randomized to either lorazepam (n = 146), diazepam\nThe algorithm starts with a stabilization phase (0\u20135 minutes), which includes standard initial first aid for seizures. The initial therapy phase should begin when the seizure duration reaches 5 minutes and should conclude by the 20-minute mark when response (or lack of response) to initial therapy\nBased on the evidence-based answers to the above questions, a treatment algorithm is proposed for convulsive status epilepticus (Figure 1). As stated earlier, clinical trials have arbitrarily focused on either adults or children, and only three trials (24, 27, 30) included both. The guideline\u2019s\nmore than 5 minutes it is likely to be prolonged (3), status treatment protocols have used a 5-minute definition to minimize both the risk of seizures reaching 30 minutes and the adverse outcomes associated with needlessly intervening on brief, self-limited seizures (2, 4). This guideline follows\nThe third therapy phase should begin when the seizure duration reaches 40 minutes. There is no clear evidence to guide therapy in this phase (level U). Compared with initial therapy, second therapy is often less effective (adults\u2014level A, one class I RCT; children\u2014level C, two class III RCTs), and\nThis guideline will address the evidence regarding the treatment of convulsive status epilepticus. For the purposes of this guideline, only studies that enrolled subjects having a seizure duration of at least 5 minutes were considered. The guideline\u2019s analysis is presented by subject age (adult\nfrom ICH and reduce the risk of seizures. A short acting opiate should be added to provide adequate analgesia. In case of concern of seizure activity, EEG monitoring should be undertaken and antiepileptic drugs administered; however, the prophylactic use of antiepileptic drugs is not warranted.",
    "ground_truth_context": "In adults with convulsive status epilepticus, intramuscular midazolam, intravenous lorazepam, intravenous diazepam and intravenous phenobarbital are established as efficacious as initial therapy (Level A). Intra-muscular midazolam has superior effectiveness compared to intravenous lorazepam in adults with convulsive status epilepticus without established intravenous access (Level A). A benzodiazepine (specifically IM mid-azolam, IV lorazepam, or IV diazepam) is recommended as the initial therapy of choice [8, 9]",
    "model_answer": "B",
    "model_answer_idx": 2,
    "correct_answer_text": "Intramuscular midazolam",
    "correct_answer_idx": 1,
    "model_reasoning": "According to the guidelines for treating convulsive status epilepticus, the initial therapy of choice is a benzodiazepine. In this case, the patient has presented with a seizure lasting 7 minutes, which qualifies as a prolonged seizure. The guidelines specifically recommend intramuscular midazolam, intravenous lorazepam, or intravenous diazepam as effective initial therapies. \n\nIntramuscular midazolam is particularly highlighted for its superior effectiveness in adults when intravenous access is not established, making it a preferred option in emergency situations. While intravenous lorazepam is also an effective choice, the context indicates that midazolam is the recommended initial therapy, especially in cases where IV access may be challenging. \n\nIntravenous phenytoin and intravenous phenobarbital are not first-line treatments for initial therapy in this scenario; they are considered alternatives or secondary options. Therefore, the best choice for initial therapy in this case is intramuscular midazolam (Option B).",
    "reasoning_ground_truth": "For convulsive status epilepticus, the guidelines recommend that a benzodiazepine (specifically IM midazolam, IV lorazepam, or IV diazepam) is the initial therapy of choice. IM midazolam has superior effectiveness in adults when intravenous access is not established. IV Phenobarbital is an alternative, not first line [8, 9].",
    "is_correct": false
  },
  {
    "question": "A 60-year-old female presents with a 6-month history of persistent nasal congestion and facial pressure. She has tried over-the-counter remedies with no relief. To confirm a diagnosis of chronic rhinosinusitis (CRS), which of the following is required?",
    "context": "The clinician should confirm a clinical diagnosis of CRS with objective documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. Strong recommendation based on cross-sectional studies with a preponderance of benefit over\n|Chronic rhinosinusitis|Twelve weeks or longer of two or more of the following signs and symptoms: \u2022 mucopurulent drainage (anterior, posterior, or both), \u2022 nasal obstruction (congestion), \u2022 facial pain-pressure-fullness, or \u2022 decreased sense of smell. AND inflammation is documented by one or more\n|7B. Objective confirmation of a diagnosis of CRS|The clinician should confirm a clinical diagnosis of CRS with objective documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography.|\nSymptoms of CRS vary in severity and prevalence. Nasal obstruction is most common (81%-95%) followed by facial congestion-pressure-fullness (70%-85%), discolored nasal discharge (51%-83%) and hyposmia (61%-69%). The presence of 2 or more signs or symptoms persisting beyond 12 weeks is highly\nClinicians should assess the patient with chronic rhinosinusitis or recurrent acute rhinosinusitis for multiple chronic conditions that would modify management such as asthma, cystic fibrosis, immunocompromised state, and ciliary dyskinesia. Recommendation based on one systematic review and multiple",
    "ground_truth_context": "The clinician should confirm a clinical diagnosis of CRS with objective documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed  tomography. [10] The purpose of this statement is to strongly emphasize that a diagnosis of CRS cannot be based on signs and symptoms alone but also requires objective evidence of sinonasal inflammation [11]",
    "model_answer": "B",
    "model_answer_idx": 2,
    "correct_answer_text": "Objective documentation of sinonasal inflammation",
    "correct_answer_idx": 1,
    "model_reasoning": "According to the guidelines provided in the context, a diagnosis of chronic rhinosinusitis (CRS) cannot be made based solely on self-reported symptoms or signs. It requires objective documentation of sinonasal inflammation, which can be achieved through methods such as anterior rhinoscopy, nasal endoscopy, or computed tomography (CT). The context explicitly states that the clinician should confirm the diagnosis with this objective evidence, emphasizing that self-reported symptoms alone are insufficient for a definitive diagnosis. Therefore, the correct answer is B, as it aligns with the requirement for objective documentation of sinonasal inflammation.",
    "reasoning_ground_truth": "The guidelines state that a diagnosis of CRS cannot be based on signs and symptoms alone, but also requires **objective evidence of sinonasal inflammation**, which can be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography [10, 11].",
    "is_correct": false
  },
  {
    "question": "A 45-year-old male with a new diagnosis of primary open-angle glaucoma is being educated about his condition. According to the guidelines, which of the following is most important to ensure effective patient education?",
    "context": "When deciding to treat a patient with glaucoma, it is important to remember that the goal of treatment is to maintain the IOP within a range at which visual field loss is unlikely to substantially reduce a patient\u2019s health-related quality of life over his or her lifetime.322\nmedications and to barriers to self-management. Ophthalmologists should remain mindful that the diagnosis of glaucoma can itself lead to negative psychological effects and to fear of blindness.691-695\n- Educate and involve the patient and appropriate family members/caregivers in the management of the disease.\n- Maintain quality of vision and preserve quality of life.\nOphthalmologists should strive to provide education that is clear, relevant, and accessible to the patient and their caregiver(s). Patients with poor health literacy skills may be especially vulnerable to worse visual outcomes.696 Limiting dense text and using \u201cteach-back\u201d techniques such as asking\ntechniques such as asking patients to explain what they understand about glaucoma may be helpful for patients with limited literacy skills. Patients with higher levels of literacy may ask questions that lead to a more complex discussion, but patients who do not understand the information provided\nPatient education through oral, written, and online information and informed participation in treatment decisions may improve adherence357 and overall effectiveness of glaucoma management. Adherence to medical therapy may be handicapped when patients run out of medication, due to inadvertent drop\nof patient education combined with personalized behavioral change interventions, including tailoring daily routines to promote adherence to eye drops, may improve adherence to glaucoma medications, overall there is insufficient evidence to recommend a particular intervention. Simplified drug\nGuidelines for follow-up of patients with POAG are summarized in Table 7. These recommendations apply to ongoing glaucoma management and not to visits for other purposes. The purpose of follow-up examination is to evaluate IOP level, visual field status, and optic disc appearance as well as ONH,",
    "ground_truth_context": "Ophthalmologists should strive to provide education that is clear, relevant, and accessible to the patient and their caregiver(s). Patients with poor health literacy skills may be especially vulnerable to worse visual outcomes.696 Limiting dense text and using \u201cteach-back\u201d techniques such as asking patients to explain what they understand about glaucoma may be helpful for patients with limited literacy skills. [12]",
    "model_answer": "C",
    "model_answer_idx": 3,
    "correct_answer_text": "Ensuring the information is clear, relevant, and accessible",
    "correct_answer_idx": 2,
    "model_reasoning": "The guidelines emphasize the importance of providing education that is **clear, relevant, and accessible** to patients and their caregivers. This approach is particularly crucial for patients with varying levels of health literacy, as those with poor health literacy may struggle to understand complex information, leading to worse visual outcomes. The context suggests that limiting dense text and employing techniques like \"teach-back\" can enhance understanding. Therefore, ensuring that the information is clear, relevant, and accessible is the most effective strategy for patient education in this scenario, making option C the correct choice.",
    "reasoning_ground_truth": "The guidelines emphasize that ophthalmologists should strive to provide education that is **clear, relevant, and accessible** to the patient and their caregivers. Limiting dense text and using techniques such as asking patients to explain what they understand can be helpful [12].",
    "is_correct": false
  },
  {
    "question": "A 50-year-old female with rheumatoid arthritis (RA) has moderate-to-high disease activity despite being treated with methotrexate. Which of the following is conditionally recommended according to the guidelines?",
    "context": "Methotrexate is conditionally recommended over alternative DMARDs for the treatment of inflammatory arthritis for patients with clinically diagnosed mild and stable airway or parenchymal lung disease, or incidental disease detected on imaging, who have moderate-to-high disease activity.\nMethotrexate is conditionally recommended over alternative DMARDs for patients with subcutaneous nodules who have moderate-to-high disease activity.  \n|Continuation of all DMARDs at their current dose|is conditionally recommended over a dose reduction of a DMARD.|\n|---|---|\nMethotrexate monotherapy is conditionally recommended over dual or triple csDMARD therapy for DMARD-naive patients with moderate-to-high disease activity. The recommendation favors methotrexate monotherapy because the higher burden of combination therapy (e.g., multiple medications, higher cost)\n|Methotrexate monotherapy is conditionally recommended over the combination of methotrexate plus a bDMARD or tsDMARD.**|Moderate/very low|PICO 6b.C1\u20134/C5\u00a7|p. 136\u201356|\n|A split dose of oral methotrexate over 24 hours or subcutaneous injections, and/or an increased dose of folic/folinic acid, is conditionally recommended over switching to alternative DMARD(s) for patients not tolerating oral weekly methotrexate.|Very low|PICO 16 and PICO 15|p. 206\u201310|\nA split dose of oral methotrexate over 24 hours or weekly subcutaneous injections, and/or an increased dose of folic/folinic acid, is conditionally recommended over switching to alternative DMARD(s) for patients not tolerating oral weekly methotrexate.\nThe recommendation is conditional because the voting panel thought that some patients who have already had persistent disease activity despite use of \u22651 csDMARD will prefer combination treatment for a more rapid response.  \nRecommendations for administration of methotrexate (Table 3)",
    "ground_truth_context": "Methotrexate monotherapy is conditionally recommended over the combination of methotrexate plus a bDMARD or tsDMARD [13]",
    "model_answer": "C",
    "model_answer_idx": 3,
    "correct_answer_text": "Continuing methotrexate monotherapy",
    "correct_answer_idx": 2,
    "model_reasoning": "According to the guidelines, for patients with moderate-to-high disease activity who are already being treated with methotrexate, the recommendation is to continue methotrexate monotherapy rather than adding a biologic DMARD, switching to a different conventional synthetic DMARD, or adding a targeted synthetic DMARD. This recommendation is based on the preference for methotrexate monotherapy due to the higher burden associated with combination therapies, which may include multiple medications and increased costs. Therefore, option C, \"Continuing methotrexate monotherapy,\" is the correct choice.",
    "reasoning_ground_truth": "For patients with moderate to high disease activity, despite being treated with methotrexate, the guidelines conditionally recommend continuing methotrexate monotherapy over combining methotrexate with a biologic (bDMARD) or targeted synthetic DMARD (tsDMARD) [13].",
    "is_correct": false
  },
  {
    "question": "A 25-year-old male is diagnosed with gonococcal urethritis.  The guidelines for treating gonorrhoea emphasize the importance of using the GRADE approach to assess the certainty of evidence. What is one way this is achieved?",
    "context": "The GRADE approach was used to assess the overall certainty of the evidence for each critical or important outcome.145 The GRADEPro Guideline Development Tool was used to create evidence profiles that categorized the overall quality of the body of evidence for each outcome into 1 of 4 categories:\nthe basis for quantifying the overall certainty of the evidence using the \u201cGrading of Recommendations Assessment, Development, and Evaluation\u201d (GRADE) approach. The penultimate version of the guideline also undergoes public review to capture additional perspectives. Thus, guidelines are the result\n|Recommendations|Strength of recommendation and quality of evidence|\n|---|---|\n|Genital and anorectal gonococcal infections| |\n|Recommendation 1|Good practice statement|\nThe quality of the evidence for the effects of treatments for gonococcal infections is low. Evidence is available from 108 studies, including 14 randomized and 94 non-randomized studies, which were conducted in a broad range of high-, middle- and low-income countries. Although high cure rates were\nThe quality of the evidence for the effects of different treatments for oropharyngeal gonococcal infections is low and very low, and therefore, overall, the evidence for this recommendation is very low. Evidence from 28 studies was identified: eight randomized and 20 non-randomized studies\n- Aggregate evidence quality: Grade B, randomized controlled trials with limitations supporting a cut-point of 7 days for lack of improvement; Grade D, expert opinion and first principles for changing therapy, including the use of rescue antibiotic in randomized controlled trials 5,132\nstrength of the total body of evidence that is available to support recommendations on a specific clinical management issue. Organizations that have adopted GRADE include SIGN, the World Health Organization, the Agency for Healthcare Research and Policy, and the American College of Physicians.3",
    "ground_truth_context": "Briefly, the GRADE approach assesses the quality of evidence for treatment interventions using well-established criteria for the design, risk of bias, inconsistency, indirectness, imprecision, effect size, dose\u2013response curve and other considerations that may affect the quality of the evidence. [14]",
    "model_answer": "C",
    "model_answer_idx": 3,
    "correct_answer_text": "By assessing the quality of evidence based on risk of bias and inconsistency.",
    "correct_answer_idx": 2,
    "model_reasoning": "The GRADE approach is a systematic method used to evaluate the quality of evidence for treatment interventions. It assesses various factors that can influence the certainty of the evidence, including risk of bias, inconsistency, indirectness, imprecision, and effect size. This comprehensive evaluation allows for a more nuanced understanding of the evidence rather than relying solely on expert opinions or limiting the analysis to randomized controlled trials. Therefore, the correct answer is that the GRADE approach achieves its assessment of evidence quality by evaluating these critical factors, specifically risk of bias and inconsistency.",
    "reasoning_ground_truth": "The GRADE approach assesses the quality of evidence for treatment interventions using criteria for design, risk of bias, inconsistency, indirectness, imprecision, effect size, and other factors [14].",
    "is_correct": false
  },
  {
    "question": "A 65-year-old male is admitted to the hospital with an acute medical illness. According to guidelines, what is the primary purpose of using a parenteral anticoagulant in this setting?",
    "context": "to prevent VTE in these adult in-hospital and outpatient medical populations who are not on chronic anticoagulants for other indications.\nany parenteral anticoagulant for VTE prevention so that the desirable consequences were greater than the undesirable consequences.\n- More information on the optimal dosing of parenteral anticoagulation to prevent VTE in medical inpatients is needed. In particular, can lower or higher doses be used in different settings (perhaps dependent on baseline risk), and should dosing be adjusted in obese patients, underweight patients,\nConclusions and research needs for this recommendation. The panel determined that there is low certainty in the evidence for a net health benefit from using any parenteral anticoagulant in acutely ill medical patients. Other EtD criteria were generally in favor of using any parenteral anticoagulant\nRecommendations 1, 2, and 3. In acutely ill medical patients, the American Society of Hematology (ASH) guideline panel suggests using UFH, LMWH, or fondaparinux rather than no parenteral anticoagulant (conditional recommendation, low certainty in the evidence of effects). Among these anticoagulants,\nIn acutely ill medical patients, the ASH guideline panel suggests using UFH, LMWH, or fondaparinux rather than no parenteral anticoagulant (conditional recommendation, low certainty in the evidence of effects \u00c5\u00c5\u25ef\u25ef). Among these anticoagulants, the panel suggests using LMWH (low certainty in the\nwere defined as those with medical conditions who may be cared for in long-term care facilities. Interventions evaluated include anticoagulants (\u201cparenterals,\u201d defined as unfractionated heparin [UFH], low-molecular-weight heparin [LMWH] or fondaparinux, and direct oral anticoagulants [DOACs]),\nIn the 2013 IUA updated guidelines, risk assessment of medically ill patients and treatment with LMWH or fondaparinux was recommended, as was consideration of postdischarge treatment of women, patients older than 75 years, or those with severe immobility. They also recommended, with moderate\nAll guidelines advocated assessing the risk of VTE and bleeding in admitted medical patients. The American College of Physicians issued 2 additional recommendations: for the use of heparin or a related drug, unless patients were at high bleeding risk, and against use of graduated compression\nStrong recommendations included provision of pharmacological VTE prophylaxis in acutely or critically ill inpatients at acceptable bleeding risk, use of mechanical prophylaxis when bleeding risk is unacceptable, against the use of direct oral anticoagulants during hospitalization, and against",
    "ground_truth_context": "The panel also considered the randomized controlled trial (RCT) by Cohen et al28 that compared fondaparinux against no parenteral anticoagulation and felt that the results were similar enough to include fondaparinux with UFH and LMWH. The EtD framework is shown online at https://dbep.gradepro.org/profile/ 54B577E9-7F80-3A78-B3EA-3850E9A1D432.[15]",
    "model_answer": "B",
    "model_answer_idx": 2,
    "correct_answer_text": "To prevent the development of venous thromboembolism (VTE)",
    "correct_answer_idx": 1,
    "model_reasoning": "The primary purpose of using a parenteral anticoagulant in acutely ill medical patients is to prevent the development of venous thromboembolism (VTE), which encompasses conditions such as deep vein thrombosis (DVT) and pulmonary embolism (PE). The guidelines specifically recommend the use of parenteral anticoagulants like UFH, LMWH, or fondaparinux for this preventive measure, indicating that the focus is on reducing the risk of VTE rather than treating existing conditions or managing bleeding events. Therefore, option B accurately reflects the intended use of parenteral anticoagulants in this clinical setting.",
    "reasoning_ground_truth": "The primary purpose of parenteral anticoagulation in acutely ill medical patients is to **prevent the development of VTE**, which includes deep vein thrombosis (DVT) and pulmonary embolism (PE) [15].",
    "is_correct": false
  },
  {
    "question": "A 60-year-old male with a history of smoking and hypertension presents with a persistent cough, fever, and shortness of breath. A chest X-ray reveals a right lower lobe infiltrate. Initial blood cultures are negative. What is the most appropriate next step in his management?",
    "context": "and symptoms of pneumonia with radiographic confirmation) to completion of antimicrobial therapy and follow-up chest imaging.\nIn Adults with CAP Who Are Improving, Should Follow-up Chest Imaging Be Obtained?\n|Routine use of follow-up chest imaging|Not addressed|Recommended not to obtain. Patients may be eligible for lung cancer screening, which should be performed as clinically indicated|\nIn adults with CAP whose symptoms have resolved within 5 to 7 days, we suggest not routinely obtaining follow-up chest imaging (conditional recommendation, low quality of evidence).\nswab is positive, coverage for MRSA pneumonia should generally be initiated, but blood and sputum cultures should be sent and therapy deescalated if cultures are negative.",
    "ground_truth_context": "our recommendations are to initially treat empirically for possible bacterial infection or coinfection. Routinely obtaining blood cultures may generate false-positive results that lead to unnecessary antibiotic use and increased length of stay.",
    "model_answer": "A",
    "model_answer_idx": 1,
    "correct_answer_text": "Start empiric antibiotic therapy for community-acquired pneumonia (CAP)",
    "correct_answer_idx": 0,
    "model_reasoning": "The patient's presentation of persistent cough, fever, and shortness of breath, along with the chest X-ray findings of a right lower lobe infiltrate, is highly suggestive of community-acquired pneumonia (CAP). According to the guidelines, the most appropriate next step in management for suspected CAP is to initiate empiric antibiotic therapy. This is crucial to address the potential bacterial infection or coinfection promptly, especially given the patient's risk factors, such as a history of smoking and hypertension.\n\nWhile blood cultures are important for identifying the causative organism, they should not delay the initiation of antibiotic treatment, as early intervention is key in managing pneumonia effectively. The other options\u2014prescribing cough suppressants, performing bronchoscopy, or ordering a CT scan\u2014are not appropriate first-line actions in this scenario. Cough suppressants do not address the underlying infection, bronchoscopy is typically reserved for more complicated cases, and a CT scan is not necessary at this stage when the diagnosis of CAP is clear based on clinical and radiographic findings. Therefore, starting empiric antibiotic therapy is the most appropriate and evidence-based next step.",
    "reasoning_ground_truth": "The patient's symptoms and chest X-ray findings are consistent with CAP. The guidelines recommend initiating **empiric antibiotic therapy** for possible bacterial infection or coinfection. Although blood cultures are recommended, they should not delay the start of antibiotic treatment. The other options are not the first-line steps for a typical CAP case.",
    "is_correct": false
  },
  {
    "question": "A 72-year-old female with known chronic kidney disease (CKD) and type 2 diabetes is admitted for a urinary tract infection. Her estimated glomerular filtration rate (eGFR) based on serum creatinine (SCr) is 35 mL/min/1.73 m\u00b2. What is the most appropriate approach for medication dosing?",
    "context": "Practice Point 4.1.2: Monitor eGFR, electrolytes, and therapeutic medication levels, when indicated, in people with CKD receiving medications with narrow therapeutic windows, potential adverse effects, or nephrotoxicity, both in outpatient practice and in hospital settings.\nMonitor eGFR, electrolytes, and therapeutic medication levels, when indicated, in people with CKD receiving medications with narrow therapeutic windows, potential adverse effects, or nephrotoxicity, both in outpatient practice and in hospital settings. Ensuring a safe use of medication requires\nMany medications and/or their active metabolites are excreted by the kidneys. Failure to properly account for the effect of GFR when designing appropriate drug-dosing regimens can predispose a person to treatment failure or adverse events. 725, 728 Although guidelines for adjustment of the dosing\nPractice Point 3.6.5: Consider reducing the dose or discontinuing ACEi or ARB in the setting of either symptomatic hypotension or uncontrolled hyperkalemia despite medical treatment, or to reduce uremic symptoms while treating kidney failure (estimated glomerular filtration rate [eGFR] &lt;15\n36. Chertow GM, Lee J, Kuperman GJ, et al. Guided medication dosing for inpatients with renal insufficiency. JAMA. 2001;286:2839\u20132844.\n37. Erler A, Beyer M, Petersen JJ, et al. How to improve drug dosing for patients with renal impairment in primary care\u2014a cluster-randomized controlled trial. BMC Fam Pract. 2012;13:91.\n1. Khanal A, Castelino RL, Peterson GM, et al. Dose adjustment guidelines for medications in patients with renal impairment: how consistent are drug information sources? Intern Med J. 2014;44:77\u201385.\nRecommendation 3.7.3: We suggest treating adults with eGFR 20 to 45 ml/min per 1.73 m2 with urine ACR <200 mg/g (<20 mg/mmol) with an SGLT2i (2B).\nWe suggest treating adults with eGFR 20 to 45 ml/min per 1.73 m2 with urine ACR <200 mg/g (<20 mg/mmol) with an SGLT2i (2B).\nPractice Point 4.2.1: Consider GFR when dosing medications cleared by the kidneys.  \nPractice Point 4.2.2: For most people and clinical settings, validated eGFR equations using SCr are appropriate for drug dosing.\nPractice Point 3.7.1: Once an SGLT2i is initiated, it is reasonable to continue an SGLT2i even if the eGFR falls below 20 ml/min per 1.73 m\u00b2, unless it is not tolerated or KRT is initiated.  \nRecommendation 3.7.2: We recommend treating adults with CKD with an SGLT2i for the following (1A):",
    "ground_truth_context": "Where more accuracy is required for drug-related decision-making (e.g., dosing due to narrow therapeutic or toxic range), drug toxicity, or clinical situations where eGFRcr estimates may be unreliable, use of equations that combine both creatinine and cystatin C, or measured GFR may be indicated.",
    "model_answer": "B",
    "model_answer_idx": 2,
    "correct_answer_text": "Use equations that combine both creatinine and cystatin C for drug dosing.",
    "correct_answer_idx": 1,
    "model_reasoning": "In the context of the 72-year-old female patient with chronic kidney disease (CKD) and an estimated glomerular filtration rate (eGFR) of 35 mL/min/1.73 m\u00b2, it is crucial to ensure accurate medication dosing due to her renal impairment. The guidelines suggest that for most individuals, validated eGFR equations using serum creatinine (SCr) are appropriate for drug dosing. However, when more accuracy is required\u2014such as in cases involving medications with narrow therapeutic windows, potential toxicity, or when eGFR estimates may be unreliable\u2014using equations that combine both creatinine and cystatin C is recommended. This approach provides a more precise assessment of kidney function, which is essential for safe and effective medication management in patients with CKD. Therefore, option B is the most appropriate approach for medication dosing in this scenario.",
    "reasoning_ground_truth": "For most people, validated eGFR equations using SCr are appropriate for drug dosing. However, when **more accuracy** is needed, such as with a narrow therapeutic range, drug toxicity, or when eGFR estimates may be unreliable, equations that combine both creatinine and cystatin C, or measured GFR may be indicated.",
    "is_correct": false
  },
  {
    "question": "A 55-year-old male presents with a first-time seizure lasting 7 minutes. He has no history of epilepsy. Intravenous (IV) access is difficult to obtain. What is the preferred initial pharmacologic treatment?",
    "context": "The following conclusions were drawn. In adults, IM midazolam, IV lorazepam, IV diazepam (with or without phenytoin), and IV phenobarbital are established as efficacious at stopping seizures lasting at least 5 minutes (level A). Intramuscular midazolam has superior effectiveness compared with IV\nThe second-therapy phase should begin when the seizure duration reaches 20 minutes and should conclude by the 40-minute mark when response (or lack of response) to the second therapy should be apparent. Reasonable options include fosphenytoin (level U), valproic acid (level B, one class II study)\nThe algorithm starts with a stabilization phase (0\u20135 minutes), which includes standard initial first aid for seizures. The initial therapy phase should begin when the seizure duration reaches 5 minutes and should conclude by the 20-minute mark when response (or lack of response) to initial therapy\nreceive a second dose of medication if the seizures continued after 10 minutes. For all patients, phenytoin was given after 30 minutes. A total of 70 patients were randomized to either lorazepam (n = 37) or diazepam (n = 33) (25). Lorazepam was successful for 78% of subjects after one dose and 89%\nor longer, or two or more GTC seizures without full recovery of consciousness. A treatment was successful if the status epilepticus stopped within 20 minutes after infusion started with no recurrence prior to 60 minutes. Overall, 570 patients were randomized to either lorazepam (n = 146), diazepam\nNine RCTs (three class I [22\u201324], one class II [25], and five class III [26\u201330]) addressed the efficacy of initial therapy. The 1998 Veteran\u2019s Affairs status epilepticus study was a multi-center randomized comparison of four different IV treatments: lorazepam (0.1 mg/kg), diazepam (0.15 mg/kg)\nIntravenous lorazepam (0.1 mg/kg over 2\u20134 minutes) was compared with IV levetiracetam (20 mg/kg over 15 minutes) in a class III RCT involving children with either convulsive or subtle convulsive status epilepticus. As first therapy, lorazepam success rate (29/38, 76.3%) was similar to that for",
    "ground_truth_context": "In adults with convulsive status epilepticus, intramuscular midazolam, intravenous lorazepam, intravenous diazepam and intravenous phenobarbital are established as efficacious as initial therapy (Level A). Intra-muscular midazolam has superior effectiveness compared to intravenous lorazepam in adults with convulsive status epilepticus without established intravenous access (Level A).",
    "model_answer": "A",
    "model_answer_idx": 1,
    "correct_answer_text": "Intramuscular midazolam",
    "correct_answer_idx": 0,
    "model_reasoning": "In the context of a 55-year-old male presenting with a first-time seizure lasting 7 minutes and with difficult intravenous (IV) access, the preferred initial pharmacologic treatment is intramuscular (IM) midazolam. According to the guidelines for treating convulsive status epilepticus, IM midazolam is recognized for its superior effectiveness compared to IV lorazepam when IV access is not readily available. While IV lorazepam is a first-line treatment for status epilepticus, the inability to establish an IV line necessitates the use of an alternative route. \n\nRectal diazepam is also a reasonable option, but IM midazolam is preferred due to its higher efficacy in this scenario. Therefore, given the circumstances of the patient's seizure and the challenges with IV access, intramuscular midazolam is the most appropriate choice.",
    "reasoning_ground_truth": "For patients with convulsive status epilepticus where **IV access is difficult**, intramuscular midazolam is superior to intravenous lorazepam. IV lorazepam is a first line treatment for status epilepticus, but if an IV line cannot be established, IM midazolam is prefered. Rectal diazepam is a reasonable alternative, but midazolam has better effectiveness when IV access is not established.",
    "is_correct": false
  },
  {
    "question": "A 48-year-old woman with a history of heavy alcohol use presents with jaundice, ascites, and confusion. She has been diagnosed with alcoholic hepatitis. What is the initial nutritional recommendation?",
    "context": "In patients with severe alcoholic hepatitis, oral intake is consistently reduced [110,111,142,181]. When the treatments are consistent in the groups, supplemental nutrition does improve infection and acute mortality, specifically in hospital deaths over ad lib oral dietary intake [186e188]. Enteral\nin patients with NAFLD [288]. These findings were not included in the AASLD/AG [120] and EASL/EASD/EASO [119] guidelines recommending only to abstain from heavy amounts of alcohol. Until evidence from intervention studies is available it seems unjustified to suggest a potential health benefit from\n47. Fialla AD, Israelsen M, Hamberg O, Krag A, Gluud LL. Nutritional therapy in cirrhosis or alcoholic hepatitis: a systematic review and meta-analysis. Liver Int Off J Int Assoc Stud Liver 2015;35(9):2072e8.\n1.2.16 Explain to people with NAFLD who drink alcohol the importance of staying within the national recommended limits for alcohol consumption.\nintake [186e188]. Enteral or supplemental feeding has been evaluated in severe alcoholic hepatitis, but no mortality benefit has been consistently reported. In the VA studies, a survival advantage to supplemental nutrition was reported in patients with malnutrition. In a meta-analysis of 13\n40. Mendenhall C, Bongiovanni G, Goldberg S, Miller B, Moore J, Rouster S, et al. VA cooperative study on alcoholic hepatitis. III: changes in protein-calorie malnutrition associated with 30 days of hospitalization with and without enteral nutritional therapy. J Parenter Enteral Nutr\n44. Nasrallah SM, Galambos JT. Aminoacid therapy of alcoholic hepatitis. Lancet 1980;2(8207):1276e7.\n45. Koretz RL, Avenell A, Lipman TO. Nutritional support for liver disease. Cochrane Database Syst Rev 2012;(5), Cd008344.\n19. Bunout D, Aicardi V, Hirsch S, Petermann M, Kelly M, Silva G, et al. Nutritional support in hospitalized patients with alcoholic liver disease. Eur J Clin Nutr 1989;43(9):615e21.\nA total of 85 recommendations were made for the nutritional and metabolic management of patients with acute liver failure, severe alcoholic steatohepatitis, non-alcoholic fatty liver disease, liver cirrhosis, liver surgery and transplantation as well as nutrition associated liver injury distinct",
    "ground_truth_context": "A total of 85 recommendations were made for the nutritional and metabolic management of patients with acute liver failure, severe alcoholic steatohepatitis, non-alcoholic fatty liver disease, liver cirrhosis, liver surgery and transplantation as well as nutrition associated liver injury",
    "model_answer": "C",
    "model_answer_idx": 3,
    "correct_answer_text": "Start enteral nutrition with a standard formula",
    "correct_answer_idx": 2,
    "model_reasoning": "The patient in question has been diagnosed with alcoholic hepatitis, which is a serious condition that requires immediate nutritional management. According to the guidelines for patients with liver disease, enteral nutrition is recommended as a safe and effective method for delivering nutritional support. Starting enteral nutrition with a standard formula is crucial for providing the necessary nutrients that the patient may not be able to obtain through oral intake due to her condition. \n\nOptions A and D, which suggest restricting fluid intake or delaying nutritional support, could potentially worsen her condition and lead to further complications. Option B, initiating a high-protein, low-carbohydrate diet, may not be appropriate without first ensuring that the patient receives adequate nutrition through enteral means, especially given her current state of health. Therefore, starting enteral nutrition with a standard formula is the most appropriate initial nutritional recommendation for this patient.",
    "reasoning_ground_truth": "The patient has signs of liver disease, which requires nutritional management. Based on the liver disease guideline, enteral nutrition should be started and is a safe route for delivery of nutritional support for patients with liver disease. Restricting fluids and or delaying nutrition may cause significant harm.",
    "is_correct": false
  },
  {
    "question": "A 50-year-old patient with a history of coronary artery disease underwent percutaneous coronary intervention (PCI) with drug-eluting stent placement. How long should dual antiplatelet therapy (DAPT) be continued?",
    "context": "recommended duration of P2Y12 inhibitor therapy (in addition to aspirin therapy). Figure 1 summarizes recommendations for duration of DAPT according to clinical status.\n|---|---|---|---|\n|In patients treated with DAPT after coronary stent implantation who subsequently undergo CABG, P2Y12 inhibitor therapy should be resumed postoperatively so that DAPT continues until the recommended duration of therapy is completed.|I|C-EO| |\nThe scope of this focused update is limited to addressing recommendations on duration of dual antiplatelet therapy (DAPT) (aspirin plus a P2Y12 inhibitor) in patients with coronary artery disease (CAD). Recommendations considered are those in 6 guidelines: \u201c2011 ACCF/AHA/SCAI Guideline for\nboth in those treated with revascularization (PCI or CABG) and in those treated with medical therapy alone (51,52). Available evidence from this trial, as well as from PLATO (53,71,72) and TRITON-TIMI 38 (54,55), supports DAPT duration of at least 12 months for patients with NSTE-ACS.\n|---|---|---|\n|I|A|In patients with STEMI treated with DAPT in conjunction with fibrinolytic therapy, P2Y12 inhibitor therapy (clopidogrel) should be continued for a minimum of 14 days (Level of Evidence: A) (140,142) and ideally at least 12 months (Level of Evidence: C-EO).|\nafter implantation (99,100). Cessation of DAPT during this period, particularly in cases of patients undergoing surgery, is associated with an unacceptable rate of often catastrophic stent thrombosis (101\u2013103). Thus, a minimum duration of DAPT of 1 month is generally recommended for patients",
    "ground_truth_context": "Most contemporary studies of DAPT have compared either shorter (3 to 6 months) (17\u201321) or longer (18 to 48 months) (16,22\u201326) duration of therapy with 12 months of DAPT, which is the recom-mended or minimal duration of therapy for most patients in ACC/AHA (9,13,14) and European Society of Cardiology (31\u201333) guidelines published between 2011 and 2014.",
    "model_answer": "C",
    "model_answer_idx": 3,
    "correct_answer_text": "12 months",
    "correct_answer_idx": 2,
    "model_reasoning": "The recommended duration of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) with drug-eluting stent placement is typically at least 12 months. This recommendation is supported by various guidelines, including those from the ACC/AHA and the European Society of Cardiology, which indicate that 12 months is the standard or minimal duration of therapy for most patients. While some studies have explored shorter (3 to 6 months) or longer (18 to 48 months) durations, the consensus remains that 12 months is the appropriate duration for DAPT in this clinical scenario. Therefore, option C (12 months) is the correct answer.",
    "reasoning_ground_truth": "For most patients, 12 months of DAPT is the recommended or minimal duration of therapy following PCI with drug-eluting stent placement. The duration can vary based on the patient profile, but 12 months is the standard recommendation.",
    "is_correct": false
  },
  {
    "question": "A 68-year-old male with a history of benign prostatic hyperplasia (BPH) and hypertension presents with new-onset fatigue, constipation, and dry skin. His TSH level is elevated, and free T4 level is low. What is the appropriate initial treatment?",
    "context": "therapy (54,55) (see L-thyroxine treatment of hypothyroidism).\nTreatment based on individual factors for patients with TSH levels between the upper limit of a given laboratory\u2019s reference range and 10 mIU/L should be considered particularly if patients have symptoms suggestive of hypothyroidism, positive TPOAb or evidence of atherosclerotic cardiovascular\nwith L-thyroxine. This has been reported in 20% of those treated with thyroid hormone (12). The principal adverse consequences of subtle or frank overtreatment are cardiovascular (187-190), skeletal (191-194), and possibly affective disturbances (195-197). The elderly are particularly susceptible to\nSee: L-thyroxine treatment of hypothyroidism\nPatients with hypothyroidism should be treated with L-thyroxine monotherapy. Grade A, BEL 1  \nSee: L-thyroxine treatment of hypothyroidism\nIn patients with central hypothyroidism, assessments of serum free T4 should guide therapy and targeted to exceed the midnormal range value for the assay being used. Grade B, BEL 3\nshould be guided by clinical response and follow up laboratory determinations including TSH values. Grade B, BEL 2\nWhen initiating therapy in patients older than 50-60 years with overt hypothyroidism, without evidence of coronary heart disease, an L-thyroxine dose of 50 \u00b5g daily should be considered. Grade D, BEL 4  \nSee: L-thyroxine treatment of hypothyroidism",
    "ground_truth_context": "The standard treatment is replacement with L-thyroxine which must be tailored to the individual patient.",
    "model_answer": "C",
    "model_answer_idx": 3,
    "correct_answer_text": "Levothyroxine (T4) monotherapy",
    "correct_answer_idx": 2,
    "model_reasoning": "The patient in the scenario is a 68-year-old male presenting with symptoms and laboratory findings consistent with primary hypothyroidism, indicated by elevated TSH levels and low free T4 levels. According to the context provided, the standard treatment for hypothyroidism is L-thyroxine (T4) monotherapy. This is supported by the guideline stating that patients with hypothyroidism should be treated with L-thyroxine monotherapy, which is considered the first-line therapy. \n\nOther options, such as Liothyronine (T3) monotherapy and combination therapy with T4 and T3, are not recommended for the majority of cases, especially in older patients. TSH injection therapy is also not a standard treatment for hypothyroidism. Therefore, the most appropriate initial treatment for this patient is Levothyroxine (T4) monotherapy.",
    "reasoning_ground_truth": "The patient's symptoms and lab results are consistent with primary hypothyroidism. The standard treatment is replacement with L-thyroxine (T4). Combination therapy with T3 is not recommended in the majority of cases.",
    "is_correct": false
  },
  {
    "question": "A 35-year-old pregnant woman, at 20 weeks gestation, presents with a new diagnosis of gonococcal infection. What is the recommended treatment?",
    "context": "Conditional  \nIn neonates with gonococcal conjunctivitis, the WHO STI guideline suggests one of the following treatment options:  \n- ceftriaxone 50 mg/kg (maximum 150 mg) IM as a single dose\n- kanamycin 25 mg/kg (maximum 75 mg) IM as a single dose\nRemarks: Treatment failures have been observed after single therapy for gonococcal oropharyngeal infections and therefore dual therapy is suggested over single therapy. This recommendation applies to pregnant women, who should be closely monitored for complications.\nRemarks: Treatment failures have been observed after single therapy for gonococcal oropharyngeal infections and therefore dual therapy is suggested over single therapy. This recommendation applies to pregnant women, who should be closely monitored for complications.\nIn neonates with gonococcal conjunctivitis, the WHO STI guideline suggests one of the following treatment options:  \n- ceftriaxone 50 mg/kg (maximum 150 mg) IM as a single dose\n- kanamycin 25 mg/kg (maximum 75 mg) IM as a single dose\n- spectinomycin 25 mg/kg (maximum 75 mg) IM as a single dose.\nIn people with gonococcal infections who have failed treatment, the WHO STI guideline suggests the following options.  \n- If reinfection is suspected, re-treat with a WHO-recommended regimen, reinforce sexual abstinence or condom use, and provide partner treatment.\nthe eventual development of untreatable gonococcal infections with serious sexual and reproductive health consequences (6). The previous WHO Guidelines for the management of sexually transmitted infections, published in 2003 (7), include ciprofloxacin as a first-line treatment for gonorrhoea, even",
    "ground_truth_context": "Six PICO questions were identified for the update on the treatment of genital, anorectal and oropharyngeal gonococcal infections, management of treatment failure, and prevention and treatment of neonatal ophthalmia (see Annex B). These questions pertained to adults and other special populations,  namely adolescents, pregnant women, people living  with HIV, and populations at high risk of acquiring  and transmitting STIs, such as men who have sex with men (MSM) and sex workers.",
    "model_answer": "B",
    "model_answer_idx": 2,
    "correct_answer_text": "Intramuscular ceftriaxone 500 mg single dose",
    "correct_answer_idx": 1,
    "model_reasoning": "The recommended treatment for gonococcal infection in pregnant women is intramuscular ceftriaxone 500 mg as a single dose. This is supported by current guidelines which emphasize the importance of using effective treatments that are safe during pregnancy. \n\n- Option A (Oral azithromycin 1 g single dose) is not recommended as a standalone treatment for gonococcal infections, especially in pregnant women, due to concerns about inadequate coverage and potential treatment failures.\n- Option C (Oral doxycycline 100 mg twice daily for 7 days) is contraindicated in pregnancy as it can affect fetal development.\n- Option D (Topical erythromycin ointment) is not an adequate treatment for systemic gonococcal infections; it is typically used for neonatal conjunctivitis but does not address the systemic nature of gonococcal infections in adults.\n\nTherefore, the most appropriate and recommended treatment for this pregnant woman with a gonococcal infection is option B: Intramuscular ceftriaxone 500 mg single dose.",
    "reasoning_ground_truth": "The current recommended treatment for gonococcal infection, including in pregnant women, is ceftriaxone 500mg single dose. Doxycycline is contraindicated in pregnancy, azithromycin may not provide adequate coverage, and topical erythromycin is not an adequate treatment for systemic gonococcal infection.",
    "is_correct": false
  },
  {
    "question": "A 50-year-old patient with rheumatoid arthritis (RA) is currently on methotrexate. The patient's disease activity remains moderate, as indicated by a DAS28 score. What is the next appropriate step in managing RA?",
    "context": "Methotrexate is conditionally recommended over alternative DMARDs for the treatment of inflammatory arthritis for patients with clinically diagnosed mild and stable airway or parenchymal lung disease, or incidental disease detected on imaging, who have moderate-to-high disease activity.\nMethotrexate is conditionally recommended over alternative DMARDs for patients with subcutaneous nodules who have moderate-to-high disease activity.  \n|Continuation of all DMARDs at their current dose|is conditionally recommended over a dose reduction of a DMARD.|\n|---|---|\nmonotherapy, preferably with methotrexate, for patients with both low and moderate/high disease activity, whereas this update recommends an initial trial of hydroxychloroquine or sulfasalazine for those with low disease activity. Second, the 2015 guidelines recommended DMARD tapering for patients\n|Methotrexate monotherapy is conditionally recommended over the combination of methotrexate plus a bDMARD or tsDMARD.**|Moderate/very low|PICO 6b.C1\u20134/C5\u00a7|p. 136\u201356|\n|Combination of methotrexate plus a non\u2013TNF inhibitor bDMARD or tsDMARD\u00b6|Low/very low|PICO 6a.C2\u20134/C5\u00a7|p. 109, 117\u201328|\n|Methotrexate monotherapy is conditionally recommended over:| | | |\n|Leflunomide|Low|PICO 2a.C3|p. 18|\n|Dual or triple csDMARD therapy\u00b6|Moderate|PICO 4a.C1\u2013C2|p. 46\u20139|\nThe recommendation is conditional because the voting panel thought that some patients who have already had persistent disease activity despite use of \u22651 csDMARD will prefer combination treatment for a more rapid response.  \nRecommendations for administration of methotrexate (Table 3)\n|A split dose of oral methotrexate over 24 hours or subcutaneous injections, and/or an increased dose of folic/folinic acid, is conditionally recommended over switching to alternative DMARD(s) for patients not tolerating oral weekly methotrexate.|Very low|PICO 16 and PICO 15|p. 206\u201310|\nA split dose of oral methotrexate over 24 hours or weekly subcutaneous injections, and/or an increased dose of folic/folinic acid, is conditionally recommended over switching to alternative DMARD(s) for patients not tolerating oral weekly methotrexate.",
    "ground_truth_context": "Methotrexate monotherapy is conditionally recommended over the combination of methotrexate plus a bDMARD or tsDMARD.",
    "model_answer": "B",
    "model_answer_idx": 2,
    "correct_answer_text": "Add a biologic or targeted synthetic DMARD to methotrexate",
    "correct_answer_idx": 1,
    "model_reasoning": "In the context of managing rheumatoid arthritis (RA), if a patient remains with moderate disease activity despite being on methotrexate, the recommended approach is to add a biologic or targeted synthetic DMARD to the existing methotrexate regimen. This is because the combination treatment can provide a more effective response for patients who have not achieved sufficient control of their disease with methotrexate alone. \n\nWhile increasing the dose of methotrexate (Option A) might be considered in some cases, the guidelines suggest that for patients with moderate-to-high disease activity, adding a second DMARD is generally more appropriate. Switching to sulfasalazine monotherapy (Option C) is not advisable since the patient is already on methotrexate, and it would not address the current moderate disease activity effectively. Prescribing a short course of oral prednisone (Option D) may provide temporary relief but does not address the underlying disease management strategy as effectively as adding a biologic or targeted synthetic DMARD.\n\nThus, the most appropriate next step in managing this patient's RA is to add a biologic or targeted synthetic DMARD to methotrexate (Option B).",
    "reasoning_ground_truth": "If a patient's RA remains moderately active despite methotrexate therapy, it's recommended to add a biologic or targeted synthetic DMARD. Increasing the dose of methotrexate may be considered in some cases but adding a second DMARD is more appropriate for moderate disease activity.",
    "is_correct": false
  },
  {
    "question": "A 62-year-old male with a history of primary open-angle glaucoma (POAG) is being treated with prostaglandin eye drops. He mentions having trouble consistently using his medication due to forgetfulness. What is the most appropriate next step?",
    "context": "of patient education combined with personalized behavioral change interventions, including tailoring daily routines to promote adherence to eye drops, may improve adherence to glaucoma medications, overall there is insufficient evidence to recommend a particular intervention. Simplified drug\nPatient education through oral, written, and online information and informed participation in treatment decisions may improve adherence357 and overall effectiveness of glaucoma management. Adherence to medical therapy may be handicapped when patients run out of medication, due to inadvertent drop\nto glaucoma treatment,347, 348 fixed combination therapy may improve patient adherence, and reduce exposure to preservatives, although it is not recommended for initial treatment in most circumstances. However, when the necessary reduction of IOP exceeds the expected efficacy of a single drug,\nAdequate treatment of glaucoma requires a high level of adherence to therapy. Frequently this is not achieved, and studies indicate relatively poor adherence to therapy.350-353 Multiple dosing requirements or side effects (such as depression, exercise intolerance, and impotence that might occur\nInstilling eye drops correctly is difficult for many patients, and their ability to do so may worsen with aging, comorbidities, and as glaucoma progresses.355, 356 Repeated instruction and counseling about proper techniques for using medication, including waiting at least 5 minutes between multiple\nAt each examination, medication dosage and frequency of use should be reviewed and recorded. Reviewing the time medication was taken may help patients link eye-drop administration to common activities of daily living and help to ensure patients are actually using their eye drops. Adherence to the\nEven patients with experience using glaucoma drops may struggle to administer drops successfully.355 Many patients depend on companions to assist with their drops.697 Ophthalmologists should consider instructing patients, and companions if applicable, on drop administration techniques. For some",
    "ground_truth_context": "Ophthalmologists should strive to provide education that is clear, relevant, and accessible to the patient and their caregiver(s).",
    "model_answer": "C",
    "model_answer_idx": 3,
    "correct_answer_text": "Encourage the use of a medication reminder system",
    "correct_answer_idx": 2,
    "model_reasoning": "The patient in this scenario is experiencing difficulties with adherence to his glaucoma medication due to forgetfulness. The most appropriate next step is to encourage the use of a medication reminder system. This approach directly addresses the issue of forgetfulness and aims to improve adherence to the prescribed treatment regimen. \n\nSwitching to a beta-blocker eye drop (Option A) or recommending laser trabeculoplasty (Option B) may not effectively resolve the underlying issue of forgetfulness and could complicate the patient's treatment plan without first attempting to improve adherence. Discontinuing treatment (Option D) is not advisable, as it would leave the patient without necessary glaucoma management, which could lead to disease progression.\n\nImplementing a medication reminder system is a practical and supportive strategy that aligns with the need for patient education and adherence improvement, as highlighted in the context provided. This method can help the patient link medication administration to daily activities, thereby enhancing the likelihood of consistent use of the eye drops.",
    "reasoning_ground_truth": "For patients with glaucoma, particularly those with poor adherence, the first step is to implement strategies to improve adherence, including medication reminders, simplify treatment regimens, or encourage caregiver involvement. Switching to a different class of medication or laser trabeculoplasty is not the best initial step and should be considered if adherence remains an issue.",
    "is_correct": false
  },
  {
    "question": "A 68-year-old male is admitted to the hospital with an acute illness. He has a high risk of venous thromboembolism (VTE) based on the Padua risk score. What is the recommended approach for VTE prophylaxis?",
    "context": "*A total of 60.3% of patients in this study were low risk (Padua score 0-3). VTE prophylaxis was administered by provider choice from among several medications and with or without concomitant compression stockings.  \nVTE incidence without VTE prophylaxis:  \n- Padua score 0 to 3: 0.3%\n- Padua score 0 to 3: 0.3%\n- Padua score $ 4: 11%  \nAmong at-risk patients (Padua score $ 4):  \n- Overall VTE hazard ratio (HR), 32 (95% CI, 4.1-251)\n- Incidence of VTE\n- - No prophylaxis: 11%\n- With prophylaxis: 2.2%\n- VTE HR with prophylaxis, 0.13 (95% CI, 0.04-0.4)\nIncidence of major or clinically relevant nonmajor bleeding with prophylaxis 5 1.6% (95% CI, 0.5-4.6)  \nInterpretation: among at-risk patients (Padua score $ 4), the reduction in VTE appears to outweigh the increased risk of bleeding with pharmacologic prophylaxis.\n\u2020Risk level: score of 0 or 1 5 low risk, score of 2 or 3 5 moderate risk; score $ 4 5 high risk. For scores $ 2, VTE prophylaxis is indicated.  \nA total of 69% of patients in this study were low risk for VTE (score 0 or 1).  \nThree-month rate of symptomatic VTE:  \n- IMPROVE VTE score 0 or 1: 0.5%\nAll guidelines advocated assessing the risk of VTE and bleeding in admitted medical patients. The American College of Physicians issued 2 additional recommendations: for the use of heparin or a related drug, unless patients were at high bleeding risk, and against use of graduated compression\n|RAM|Points|\n|---|---|\n|Padua VTE RAM: score \u20214 indicates high VTE risk*| |\n|Reduced mobility|3|\n|Active cancer|3|\n|Previous VTE (excluding superficial thrombophlebitis)|3|\n|Known thrombophilic condition|3|\n|Recent trauma and/or surgery (,1 mo)|2|\n|Elderly age (ie, .70 y)|1|\nThe 2017 Asian Venous Thrombosis Forum updated guidelines for medically ill patients concluded that, if prophylaxis was used, pharmacological prophylaxis was preferred in the absence of bleeding risk; otherwise, intermittent pneumatic compression, but not graduated compression stockings, were",
    "ground_truth_context": "We found 17 systematic reviews that addressed this question,51-67 with 25 studies29,30,68-89 (H. Vissinger and S. Husted, unpublished data, 1995) in these reviews evaluating outcomes relevant to this question.",
    "model_answer": "C",
    "model_answer_idx": 3,
    "correct_answer_text": "Pharmacological prophylaxis with parenteral anticoagulation",
    "correct_answer_idx": 2,
    "model_reasoning": "The context indicates that patients with a high risk of venous thromboembolism (VTE), as determined by the Padua risk score, should receive pharmacological prophylaxis with parenteral anticoagulation. This is supported by the guidelines which recommend the use of anticoagulants for VTE prophylaxis in acutely ill patients at high risk, unless there is a high risk of bleeding. While mechanical prophylaxis (such as compression stockings) may be considered in cases where anticoagulation is contraindicated or as an adjunct therapy, it is not the first-line strategy for high-risk patients. Therefore, the most appropriate and recommended approach for this 68-year-old male patient with a high risk of VTE is pharmacological prophylaxis with parenteral anticoagulation.",
    "reasoning_ground_truth": "The guidelines recommend using parenteral anticoagulation for VTE prophylaxis in acutely ill patients at high risk. Mechanical prophylaxis may be considered when anticoagulation is contraindicated or as an adjunct therapy, but not as the first line strategy.",
    "is_correct": false
  },
  {
    "question": "A 58-year-old male with a history of chronic kidney disease (CKD) is being evaluated for kidney function. His eGFR based on creatinine is 40 mL/min/1.73m^2. What additional test should be considered?",
    "context": "Following incidental detection of elevated urinary albumin-to-creatinine ratio (ACR), hematuria, or low estimated GFR (eGFR), repeat tests to confirm presence of CKD.\nIdentify adults at risk for CKD  \nTest for GFR* and ACR \u00b1 other markers of kidney damage \u2020  \nGFR &lt;60 ml/min per 1.73 m2 or ACR \u226530 mg/g [3 mg/mmol]2 and/or other markers of kidney damage present  \nTest for GFR or ACR if not performed and exclude AKI/AKD\nPractice Point 1.1.1.2: Following incidental detection of elevated urinary albumin-to-creatinine ratio (ACR), hematuria, or low estimated GFR (eGFR), repeat tests to confirm presence of CKD.\nand urine to detect CKD is important, with confirmatory testing if initial findings indicate the presence of abnormalities of creatinine/eGFR or albuminuria.\ndecisions as an assessment of excretory kidney function (Table 4) to detect and stage AKD and CKD, determine CKD progression, dose medications, determine appropriate use of diagnostic tests, and guide treatment decisions around KRT therapies. Equations are available that estimate GFR using SCr and\nImplications for aging adults with CKD are important in both diagnosis and treatment. The interpretation of laboratory results (specifically SCr) used in the staging system should factor in an older adult\u2019s habitus given the frequency of sarcopenia. A creatinine-based eGFR (eGFRcr) will\ndata were anto mGFR most consistently (i) review of past measurements/estimations of GFR; (ii) review of past measurements of albuminuria or proteinuria and urine microscopic examinations; (iii) imaging findings such as reduced kidney size and reduction in cortical thickness; (iv) kidney",
    "ground_truth_context": "If eGFRcr is expected to be inaccurate, or if a more accurate assessment of GFR is needed for clinical decision-making, such as diagnosis or staging of chronic kidney disease or drug dosing, then, if available, cystatin C should be measured, and creatinine and cystatin C\u2013based estimated GFR (eGFRcr-cys) should be estimated.",
    "model_answer": "B",
    "model_answer_idx": 2,
    "correct_answer_text": "Measure cystatin C to estimate eGFR",
    "correct_answer_idx": 1,
    "model_reasoning": "In the context of evaluating kidney function for a patient with chronic kidney disease (CKD) and an eGFR of 40 mL/min/1.73m\u00b2, it is important to ensure the accuracy of the estimated GFR. The initial test for GFR is typically based on creatinine levels (eGFRcr). However, if there are concerns that the creatinine-based estimate may not accurately reflect the patient's kidney function\u2014due to factors such as muscle mass, age, or other individual characteristics\u2014measuring cystatin C can provide a more reliable estimate of GFR. \n\nCystatin C is a protein that is produced at a constant rate by all nucleated cells and is filtered by the kidneys, making it a useful marker for kidney function. If the eGFR based on creatinine is suspected to be inaccurate, measuring cystatin C and calculating the cystatin C-based eGFR (eGFRcr-cys) is recommended for a more precise assessment.\n\nThe other options are less appropriate in this scenario:\n- A. Repeating the creatinine-based eGFR in 3 months does not address the potential inaccuracies in the current measurement.\n- C. Performing a kidney biopsy is not indicated unless the cause of CKD is uncertain, which is not the case here.\n- D. Starting renal replacement therapy is not warranted unless the eGFR is significantly lower or the patient is experiencing severe symptoms related to kidney failure.\n\nThus, measuring cystatin C to estimate eGFR is the most appropriate next step in this evaluation.",
    "reasoning_ground_truth": "The initial test for evaluating GFR is eGFRcr. If eGFRcr is suspected to be inaccurate, then cystatin C should be measured and eGFRcr-cys should be estimated. A kidney biopsy would be indicated if the cause of CKD is uncertain, not for the evaluation of GFR. Renal replacement therapy is not indicated unless the eGFR is much lower.",
    "is_correct": false
  },
  {
    "question": "A 42-year-old female with a history of migraine presents with frequent, severe headaches. She has tried several abortive therapies with limited success. What is the next step in her management?",
    "context": "Objective: To provide updated evidence-based recommendations for the preventive treatment of migraine headache. The clinical question addressed was: What pharmacologic therapies are proven effective for migraine prevention?\nmigraine prevention, similar evidence is unavailable to help the practitioner choose one therapy over another. Treatment regimens, therefore, need to be designed case by case, which may include complex or even nontraditional approaches. Moreover, decision-making must remain with the physician and\nThe following medications are established as effective and should be offered for migraine prevention:  \n- Antiepileptic drugs (AEDs): divalproex sodium, sodium valproate, topiramate\n- \u03b2-Blockers: metoprolol, propranolol, timolol\n- Triptans: frovatriptan for short-term MAMs prevention\nThe following medications are probably effective and should be considered for migraine prevention:  \n- Antidepressants: amitriptyline, venlafaxine\n- \u03b2-Blockers: atenolol, nadolol\n- Triptans: naratriptan, zolmitriptan for short-term MAMs prevention\nStudies are needed that specifically evaluate when preventive therapy is warranted and how medications should be titrated. Table e-1 lists some specific consensus-based clinical circumstances wherein considering preventive therapy would be reasonable. A shortcoming of migraine prevention clinical\n- Assessed the efficacy of therapeutic agents for headache other than episodic migraine in adults\n- Assessed acute migraine treatment, migraine aura treatment/prevention, or nonpharmacologic treatments (e.g., behavioral approaches)\nmigraine prevention clinical studies is the relatively brief treatment duration (often only 12\u201316 weeks). Long-term assessment of the efficacy and safety of migraine preventive treatments is needed. Additionally, overall cost is a consideration when prescribing medications; cost may influence",
    "ground_truth_context": "Evidence to support pharmacologic treatment strategies for migraine prevention indicates which treatments might be effective but is insufficient to establish how to choose an optimal therapy.",
    "model_answer": "A",
    "model_answer_idx": 1,
    "correct_answer_text": "Initiate a preventative migraine therapy",
    "correct_answer_idx": 0,
    "model_reasoning": "The context indicates that for patients experiencing frequent and severe migraines, especially when abortive therapies have proven ineffective, the next step in management should be to initiate a preventative migraine therapy. This aligns with the evidence-based recommendations that suggest considering preventative treatments when abortive medications do not provide sufficient relief. The other options are not appropriate; referring for neurosurgery is typically reserved for more severe cases or specific conditions, prescribing a higher dose of abortive medication may not address the underlying issue of frequent migraines, and recommending lifestyle modifications alone would not be sufficient given the patient's history of limited success with abortive therapies. Therefore, the most appropriate next step is to initiate a preventative migraine therapy.",
    "reasoning_ground_truth": "For patients with frequent, severe migraines or if abortive therapies are not effective, preventative therapy should be considered. Other options are not appropriate at this stage.",
    "is_correct": false
  },
  {
    "question": "A 30-year-old male presents with a 3-day history of nasal congestion, facial pain, and purulent nasal discharge. He reports no improvement after using over-the-counter decongestants. What is the most appropriate initial management strategy?",
    "context": "Oral decongestants may provide symptomatic relief and should be considered barring any medical contraindications, such as hypertension or anxiety. The use of topical decongestant is likely to be palliative, but continuous duration of use should not exceed 3 to 5 days, as recommended by the\ndocumentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. The update group made recommendations that clinicians (1) should either offer watchful waiting (without antibiotics) or prescribe initial antibiotic therapy for\nAdjunctive treatments for rhinosinusitis that may aid in symptomatic relief include analgesics, decongestants (\u03b1-adrenergic), corticosteroids, saline irrigation, and mucolytics. None of these products has been specifically approved by the FDA for use in acute rhinosinusitis (as of March 2014), and\nagents, nasal saline, decongestants, antihistamines, mucolytics, cough suppressants, and topical or oral corticosteroids\u2014may be used alone or in varying combinations for symptom relief.\nand nasal mucosa on imaging studies65,108 and is superior to a single orally administered dose of pseudoephedrine.108 Another small, nonrandomized study showed improved outcomes when xylometazoline spray was added to antibiotics for ABRS.97 Topical decongestants should not be used more than 3 to 5\nnasal drainage accompanied by nasal obstruction, facial pain-pressure-fullness, or both) persist without\nClinicians may recommend analgesics, topical intranasal steroids, and/or nasal saline irrigation for symptomatic relief of VRS. Option based on randomized controlled trials with limitations and cohort studies with an unclear balance of benefit and harm that varies by patient.",
    "ground_truth_context": "Extension of watchful waiting (without antibiotic therapy) as an initial management strategy to all patients with uncomplicated acute bacterial rhi-nosinusitis (ABRS) regardless of severity, not just patients with \u201cmild\u201d illness (prior guideline).",
    "model_answer": "C",
    "model_answer_idx": 3,
    "correct_answer_text": "Recommend watchful waiting for 7 days",
    "correct_answer_idx": 2,
    "model_reasoning": "The patient's symptoms of nasal congestion, facial pain, and purulent nasal discharge suggest a case of uncomplicated acute bacterial rhinosinusitis (ABRS). According to the guidelines, the initial management strategy for uncomplicated ABRS is to recommend watchful waiting for a period of 7 days. This approach is appropriate because antibiotics are not indicated immediately unless symptoms do not improve after this period. Starting antibiotic therapy right away (Option A) is not recommended in this case, as it may lead to unnecessary antibiotic use. Prescribing nasal corticosteroids (Option B) could provide some relief, but it is not the first-line recommendation in this scenario. Ordering a sinus CT scan (Option D) is also unnecessary at this stage, as imaging is typically reserved for cases with complications or when symptoms persist despite appropriate management. Therefore, the most appropriate initial management strategy is to recommend watchful waiting for 7 days (Option C).",
    "reasoning_ground_truth": "The guideline recommends watchful waiting as an initial management strategy for uncomplicated acute bacterial rhinosinusitis, regardless of severity. Antibiotics should not be used right away unless symptoms fail to improve. A CT scan is not required at this stage.",
    "is_correct": false
  },
  {
    "question": "A 55-year-old male with a long history of sun exposure presents with several rough, scaly lesions on his scalp and face. He is diagnosed with actinic keratoses (AKs). What is the recommended initial treatment?",
    "context": "Actinic keratoses are keratinocyte neoplasms occurring on skin that has had long-term exposure to ultraviolet radiation.\ncombined with vehicle applied twice daily for 4 consecutive days for the field treatment of AKs on the face, scalp, and upper extremities. Although outside the scope of the present guidelines, which are focused on currently available treatment options, the Work Group considered the evidence to be\n|Jorizzo 2006|Face or scalp|Field|Cream|0.5|1/d|7 d|\n|Pomerantz 2015|Face|Field|Cream|5|2/d|28 d|\n|Weiss 2002|Face or scalp|Field|Cream|0.5|1/d|7, 14, or 28 d|\n|Imiquimod|Face or scalp|Field|Cream|5|3/wk|4 or 8 wks (1 or 2 courses)|\nActinic keratosis (AK) is one of the most common conditions diagnosed and treated by dermatologists in the United States (US). These guidelines address the management of AK from the perspective of US dermatologists, other practitioners who treat AK, and patients. Premalignant neoplasia on\nrecognized to be at increased risk for the development of cutaneous malignancies, particularly SCC.138,139 A lack of evidence prevented development of recommendations for treatment in this patient population. The high level of evidence required from larger RCTs can be difficult to achieve for\nFormulation of questions and rating the importance of outcomes. The expert Work Group identified 5 clinical questions on the management of actinic keratoses using the Population, Intervention, Comparator, Outcome (PICO) format (Table V). After selecting the questions that would be addressed in the\nThe literature on AK treatment supports a strong recommendation for field treatment with either 5-fluorouracil (5-FU) or imiquimod.\nAnalysis of the evidence from this systematic review based on 5 research questions resulted in 18 evidence-based recommendations and suggests there are several effective treatments available for AK. Strong recommendations were made for the use of UV protection, cryosurgery, topical imiquimod, and",
    "ground_truth_context": "Clinical question (CQ) 1 asks: Should topically applied agents be used for the treatment of AKs?.",
    "model_answer": "C",
    "model_answer_idx": 3,
    "correct_answer_text": "Topical application of a medication approved for AKs",
    "correct_answer_idx": 2,
    "model_reasoning": "The context provided indicates that actinic keratoses (AKs) are commonly treated with topical medications, specifically mentioning 5-fluorouracil (5-FU) and imiquimod as strong recommendations for field treatment. The question asks for the recommended initial treatment for a patient diagnosed with AKs, and the options include various treatment modalities. \n\nSurgical excision (Option A) is typically reserved for more advanced lesions or when there is a suspicion of malignancy, rather than as an initial treatment for AKs. Cryotherapy (Option B) is a valid treatment option but is not the first-line recommendation according to the guidelines mentioned. Observation (Option D) is not appropriate for AKs, as they are premalignant lesions that require intervention.\n\nTherefore, the most appropriate and recommended initial treatment for AKs, as indicated in the context, is the topical application of a medication approved for AKs (Option C). This aligns with the standard first-line treatment approach for managing actinic keratoses.",
    "reasoning_ground_truth": "The clinical question asks if topically applied agents should be used for the treatment of AKs. Topical therapy is a standard first line treatment option for AK's.",
    "is_correct": false
  },
  {
    "question": "A 45-year-old patient with chronic kidney disease (CKD) and type 2 diabetes is starting on a new antihypertensive medication. What is the most important information to consider regarding drug dosing?",
    "context": "In particular, can lower or higher doses be used in different settings (perhaps dependent on baseline risk), and should dosing be adjusted in obese patients, underweight patients, and patients with renal disease?\nPractice Point 3.6.5: Consider reducing the dose or discontinuing ACEi or ARB in the setting of either symptomatic hypotension or uncontrolled hyperkalemia despite medical treatment, or to reduce uremic symptoms while treating kidney failure (estimated glomerular filtration rate [eGFR] &lt;15\nAppropriate dosing of medications according to different biological parameters in people with CKD is critical to evaluating benefits and risks; thus, studies targeted at answering these questions will be valuable.\nrecommended for younger people with CKD, as they may not necessarily be transferable to older adults. Strict BP-lowering, for example, may come with the risk of dizziness, falls, and fractures in older adults, many of whom are on anticoagulants risking severe hemorrhage.\nConsider reducing the dose or discontinuing ACEi or ARB in the setting of either symptomatic hypotension or uncontrolled hyperkalemia despite medical treatment, or to reduce uremic symptoms while treating kidney failure (estimated glomerular filtration rate [eGFR] <15 ml/min per 1.73 m2).",
    "ground_truth_context": "An assessment of GFR is important for guiding decisions related to the choice and dosing of medications. Section 1.2 addresses the accuracy of validated eGFR equations, as well as indications for the use of eGFRcr-cys or mGFR.",
    "model_answer": "C",
    "model_answer_idx": 3,
    "correct_answer_text": "The patient's estimated glomerular filtration rate (eGFR)",
    "correct_answer_idx": 2,
    "model_reasoning": "The patient's estimated glomerular filtration rate (eGFR) is crucial for guiding decisions related to the choice and dosing of medications in patients with chronic kidney disease (CKD). Medications that are renally cleared may require dose adjustments based on the eGFR to avoid toxicity and ensure efficacy. In the context of CKD, understanding the patient's kidney function is more relevant than factors such as liver metabolism, the need for a loading dose, or the current blood pressure reading. Therefore, option C is the most important information to consider regarding drug dosing in this scenario.",
    "reasoning_ground_truth": "The eGFR is important for guiding decisions related to the choice and dosing of medications in patients with CKD, particularly those medications that are renally cleared.",
    "is_correct": false
  },
  {
    "question": "A 68-year-old woman with a recent diagnosis of community acquired pneumonia (CAP) is being discharged from the hospital. She has multiple comorbidities. Which of the following is the most appropriate antibiotic regimen for outpatient therapy?",
    "context": "In the Inpatient Setting, Which Antibiotic Regimens Are Recommended for Empiric Treatment of CAP in Adults without Risk Factors for MRSA and P. aeruginosa?\nLonger courses of antibiotic therapy are recommended for 1) pneumonia e59\nIn the Outpatient Setting, Which Antibiotics Are Recommended for Empiric Treatment of CAP in Adults?\nFor adults with community-acquired pneumonia (CAP) at risk for MRSA or P. aeruginosa (see Recommendation 11), we recommend the following empiric treatment regimens (in no order of preference) (Table 4):\nRegimens recommended for patients with comorbidities include a b-lactam or cephalosporin in combination with either a macrolide or doxycycline. These combinations should effectively target macrolide- and doxycycline-resistant S. pneumoniae (as b-lactam resistance in S. pneumoniae remains less\nIn Outpatient and Inpatient Adults with CAP Who Are Improving, What Is the Appropriate Duration of Antibiotic Treatment?",
    "ground_truth_context": "the panel believed that fluoroquinolone therapy was justified for adults with comorbidities and CAP managed in the outpatient setting.",
    "model_answer": "C",
    "model_answer_idx": 3,
    "correct_answer_text": "A fluoroquinolone",
    "correct_answer_idx": 2,
    "model_reasoning": "For patients with community-acquired pneumonia (CAP) who have multiple comorbidities, it is essential to provide a broader-spectrum antibiotic regimen to ensure adequate coverage against potential pathogens, including those that may be resistant. According to the guidelines, a respiratory fluoroquinolone is recommended for outpatient therapy in such cases. \n\nMonotherapy options like amoxicillin, azithromycin, or doxycycline are generally suitable for patients without comorbidities, but they may not provide sufficient coverage for all CAP pathogens in patients with comorbidities. Therefore, the most appropriate choice for this 68-year-old woman with multiple comorbidities is a fluoroquinolone, which offers a more comprehensive treatment option.",
    "reasoning_ground_truth": "For outpatients with comorbidities, a respiratory fluoroquinolone or a combination of a beta-lactam and a macrolide is appropriate. Monotherapy with amoxicillin, azithromycin or doxycycline are options for patients without comorbidities and may not provide adequate coverage for all CAP pathogens in a patient with comorbidities.",
    "is_correct": false
  },
  {
    "question": "A 70-year-old man with a history of heart failure is hospitalized for an acute exacerbation. He develops acute kidney injury. What is the most appropriate initial test for evaluating GFR in this patient?",
    "context": "Practice Point 1.1.1.1: Test people at risk for and with chronic kidney disease (CKD) using both urine albumin measurement and assessment of glomerular filtration rate (GFR).\nPractice Point 1.1.1.1: Test people at risk for and with chronic kidney disease (CKD) using both urine albumin measurement and assessment of glomerular filtration rate (GFR).\nFigure 11 | Approach to glomerular filtration rate (GFR) evaluation using initial and supportive tests. The algorithm describes the approach to the evaluation of GFR. The approach uses initial and supportive testing to develop a final assessment of true GFR and to apply it in individual\nGFR (eGFRcr-cys) should be estimated. If eGFRcr-cys is expected to be inaccurate, or if an even more accurate assessment of GFR is needed for clinical decision-making, then, if available, GFR should be measured using plasma or urinary clearance of exogenous filtration markers. *Initial test may be\nExcretory function but is widely accepted as the best overall index of kidney function because it is generally reduced after widespread structural damage and most other kidney functions decline in parallel with GFR in CKD.\nPractice Point 2.2.1: A 5-year kidney failure risk of 3%\u20135% can be used to determine need for nephrology referral in addition to criteria based on eGFR or urine ACR, and other clinical considerations.\nA 2-year kidney failure risk of >10% can be used to determine the timing of multidisciplinary care in addition to eGFR-based criteria and other clinical considerations.\nA 2-year kidney failure risk of >10% can be used to determine the timing of multidisciplinary care in addition to eGFR-based criteria and other clinical considerations.\n|Most used method to assess GFR. In most cases, initial test for the evaluation of GFR. Standardized assay required to decrease between-center analytical variation|Most used method to assess GFR. In most cases, initial test for the evaluation of GFR. Standardized assay required to decrease\nBetter-preserved GFRs, earlier blood sampling is most accurate, and in people with extensive edema or ascites, plasma clearance protocols are very inaccurate and not recommended; instead, urinary clearance protocols are recommended. Finally, it is well recognized that assessing GFR using the\ndecision-making. The initial test for the evaluation of GFR is creatinine-based estimated GFR (eGFRcr), which will be available for most people because creatinine is measured routinely as part of the basic metabolic panel. If eGFRcr is expected to be inaccurate, or if a more accurate assessment of",
    "ground_truth_context": "As in the previous KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease,1 the first method to evaluate GFR should be eGFRcr. If necessary for greater accuracy, the approach then recommends subsequent supportive tests from either the more accurate eGFRcr-cys or measurement of GFR using urinary or plasma clearance of exogenous filtration markers.",
    "model_answer": "C",
    "model_answer_idx": 3,
    "correct_answer_text": "eGFR based on serum creatinine (eGFRcr)",
    "correct_answer_idx": 2,
    "model_reasoning": "The initial test for evaluating glomerular filtration rate (GFR) in patients, including the 70-year-old man with acute kidney injury, is the estimated GFR based on serum creatinine (eGFRcr). This is the standard first-line approach as it is routinely available and provides a quick assessment of kidney function. \n\nWhile cystatin C (eGFRcys) can be used as a supportive test if there are concerns about the accuracy of eGFRcr, it is not the first test to be performed. Measured GFR using exogenous filtration markers is typically reserved for situations where a more accurate assessment is necessary, and a renal ultrasound is not used for evaluating GFR but may be indicated for assessing the cause of acute kidney injury. Therefore, the most appropriate initial test for evaluating GFR in this patient is eGFR based on serum creatinine (eGFRcr).",
    "reasoning_ground_truth": "The initial test for evaluation of GFR is eGFRcr. Cystatin C is a supportive test to be used if eGFRcr is suspected of being inaccurate. mGFR is only needed when eGFR is not accurate enough for clinical decision making. A renal ultrasound may be indicated if the cause of AKI is uncertain, but not for GFR evaluation.",
    "is_correct": false
  },
  {
    "question": "A 50-year-old female with a recent diagnosis of CKD is being educated about her condition. What is the most important aspect to address in her education?",
    "context": "when addressing key questions that impact people living with or at risk for CKD.\nCKD G1\u2013G2\nCKD G3\u2013G4\nCKD G5\nFigure 53 | Strategy for effective patient education programs for people with chronic kidney disease (CKD). *Should be tailored to individual needs and wishes. KRT, kidney replacement therapy.\nPractice Point 3.11.5.1: Implement an individualized approach in people with CKD G3\u2013G5 and emergent hyperkalemia that includes dietary and pharmacologic interventions and takes into consideration associated comorbidities and quality of life (QoL). Assessment and education through a renal dietitian\nPractice Point 3.11.5.1: Implement an individualized approach in people with CKD G3\u2013G5 and emergent hyperkalemia that includes dietary and pharmacologic interventions and takes into consideration associated comorbidities and quality of life (QoL). Assessment and education through a renal dietitian\n- Improving CKD awareness\n- Empower self-management\n- Management of CKD complications\n- Target high-risk people with CKD\n- Triage patient to specific educational topics they need\n- Engage family members and/or caregivers\nPractice Point 3.1.1: Treat people with CKD with a comprehensive treatment strategy to reduce risks of progression of CKD and its associated complications (Figure 17).\nEducation programs that also involve care partners where indicated are important to promote informed, activated people with CKD.  \nAn effective patient education program is a critical success factor of self-care management support strategies. Education should address 3 main issues:",
    "ground_truth_context": "Standardized educational topics should cover 3 main subject areas: knowledge about CKD, knowledge about treatment to slow progression and complications of CKD, and knowledge about the kidney failure management options.",
    "model_answer": "D",
    "model_answer_idx": 4,
    "correct_answer_text": "The etiology of CKD, its management, and the available kidney failure management options",
    "correct_answer_idx": 3,
    "model_reasoning": "The most important aspect to address in the education of a patient with chronic kidney disease (CKD) is the etiology of CKD, its management, and the available kidney failure management options. This is crucial for empowering the patient with knowledge about their condition, which is essential for effective self-management. \n\nEducational programs for CKD patients should cover three main areas: understanding CKD itself (including its causes), strategies to slow its progression and manage complications, and the options available for kidney failure management. By focusing on these areas, patients can better understand their health, make informed decisions about their care, and engage in self-management practices that can improve their quality of life.\n\nWhile detailed kidney anatomy, specific dietary restrictions, and the type of kidney failure and its treatment options are important topics, they are secondary to the comprehensive understanding of CKD's etiology and management. This foundational knowledge is necessary for patients to grasp the implications of their diagnosis and the importance of adhering to treatment plans and lifestyle modifications.",
    "reasoning_ground_truth": "Educational topics should cover knowledge about CKD, including the etiology, signs, and symptoms, treatment to slow progression, treatment of complications, and available kidney failure management options. Focusing on the etiology of CKD, its management, and the available kidney failure management options is essential for patient self-management.",
    "is_correct": false
  },
  {
    "question": "A 35-year-old male presents with a 2-day history of fever, cough, and shortness of breath. He is diagnosed with community-acquired pneumonia (CAP). He is admitted to the hospital.  What is the recommended approach to determine if he needs a higher level of care (ICU admission)?",
    "context": "The 2007 IDSA/ATS CAP guidelines recommended a set of two major and nine minor criteria to define severe pneumonia requiring ICU admission (Table 1). These criteria were based on empirical evidence from published studies and expert consensus. All elements are routinely available in emergency\nprompt assessment for a pathogen resistant to the current therapy and/or complications of pneumonia (e.g., empyema or lung abscess) or for an alternative source of infection and/or inflammatory response (208, 209). When assessment of clinical stability has been introduced into clinical practice,\nurea level, respiratory rate, blood pressure, and age &gt;=65) (conditional recommendation, low quality of evidence), to determine the need for hospitalization in adults diagnosed with CAP.\nBoth the PSI and CURB-65 were developed as prognostic models in immunocompetent patients with pneumonia, using patient demographic and clinical variables from the time of diagnosis to predict 30-day mortality (39, 40). When compared with CURB-65, PSI identifies larger proportions of patients as low\nShould a Clinical Prediction Rule for Prognosis plus Clinical Judgment versus Clinical Judgment Alone Be Used to Determine Inpatient General Medical versus Higher Levels of Inpatient Treatment Intensity (ICU, Step-Down, or Telemetry Unit) for Adults with CAP?\nIn addition to clinical judgement, we recommend that clinicians use a validated clinical prediction rule for prognosis, preferentially the Pneumonia Severity Index (PSI) (strong recommendation, moderate quality of evidence) over the CURB-65 (tool based on confusion, urea level, respiratory rate,\nwith CAP has potential to decrease unnecessary variability in admission rates, the high cost of inpatient pneumonia treatment (53, 54), and the risk of hospital-acquired complications.",
    "ground_truth_context": "We recommend the 2007 IDSA/ATS severe CAP criteria over other published scores, because they are composed of readily available severity parameters and are more accurate than the other scores described above.",
    "model_answer": "A",
    "model_answer_idx": 1,
    "correct_answer_text": "Use a clinical prediction tool plus clinical judgment.",
    "correct_answer_idx": 0,
    "model_reasoning": "The 2007 IDSA/ATS guidelines recommend using a clinical prediction tool, such as the severe pneumonia criteria, in conjunction with clinical judgment to assess the need for ICU admission in patients diagnosed with community-acquired pneumonia (CAP). This approach is supported by empirical evidence and expert consensus, making it the most reliable method for determining the appropriate level of care. Relying solely on clinical judgment (Option B) may lead to variability in admission rates and potentially overlook critical indicators of severity. Using a serum procalcitonin test (Option C) or waiting for blood culture results (Option D) does not align with the recommended evidence-based approach for immediate assessment of the patient's condition. Therefore, the best practice is to combine a validated clinical prediction tool with clinical judgment, which is reflected in Option A.",
    "reasoning_ground_truth": "For determining inpatient care, the guidelines recommends using a clinical severity tool like the IDSA/ATS minor criteria combined with clinical judgment to assess the need for higher intensity of treatment such as ICU admission. Other options do not use the best evidence based approach.",
    "is_correct": false
  },
  {
    "question": "A 58-year-old patient with CKD is being evaluated for the cause of his condition. After initial evaluation, a kidney biopsy is being considered. When is it most appropriate to perform a kidney biopsy?",
    "context": "This recommendation places a high value on an acceptable safety profile of kidney biopsies when used to evaluate the cause of CKD and to plan appropriate treatment.\nTesting for CKD without regard to age generates controversy. Those in older age groups experience the greatest burden of CKD and are also at the highest risk for cardiovascular complications. As with other detection programs like cancer detection, CKD detection efforts should be individualized\nWhat is the diagnostic and prognostic bene\ufb01t and safety of kidney biopsy among people with CKD?\nDetermine the prevalence of kidney biopsy\u2013related complications in different clinical circumstances (age, size of kidneys, acute vs. chronic, and comorbidities) to inform risk estimates appropriate to those in the current era dependent on methods (e.g., blind, ultrasound-guided, CT-guided, open, and\nValues and preferences. The Work Group judged that many people with CKD would choose to undergo a kidney biopsy to establish the cause of their CKD more accurately and potentially offer prognostic information. Thus, this recommendation puts a high value on the specificity of a kidney biopsy for the\nWe suggest performing a kidney biopsy as an acceptable, safe, diagnostic test to evaluate cause and guide treatment decisions when clinically appropriate.",
    "ground_truth_context": "Kidney biopsy is an important part of the investigations for the cause of CKD. It is often deferred because of the potential for harm or lack of recognition of potential utility. The evi-dence to support safety of biopsy is heterogeneous and therefore uncertain, but in the studies evaluated, appears to confer low risk of harm, supporting our suggestion that kidney biopsies should be considered when it is thought that they can provide information to identify cause, facilitate prognostication, and inform treatment strategies.",
    "model_answer": "B",
    "model_answer_idx": 2,
    "correct_answer_text": "When it is thought that it can provide information for cause and treatment.",
    "correct_answer_idx": 1,
    "model_reasoning": "A kidney biopsy is most appropriate when it is believed that the procedure can provide valuable information regarding the underlying cause of chronic kidney disease (CKD) and assist in determining the appropriate treatment options. The context emphasizes that kidney biopsies should be considered when they can help identify the cause, facilitate prognostication, and inform treatment strategies. The other options do not accurately reflect the rationale for performing a kidney biopsy. For instance, the eGFR value alone (option A) does not dictate the need for a biopsy, and while diabetes can be a cause of CKD (option C), it does not justify a biopsy without the potential for additional information. Option D suggests that a biopsy should only be performed after exhausting all other tests, which is not aligned with the recommendation that a biopsy can be beneficial when it can provide critical insights into the patient's condition. Thus, option B is the most appropriate choice.",
    "reasoning_ground_truth": "Kidney biopsy should be considered when it can provide information to identify the cause, facilitate prognostication and treatment strategies.. The eGFR value does not dictate the need for a biopsy. Other options are not the correct reason for performing a biopsy.",
    "is_correct": false
  },
  {
    "question": "A 65-year-old male with a history of atrial fibrillation and CKD is being started on anticoagulation. What is the most appropriate approach for selecting the medication?",
    "context": "limited pharmacokinetic and pharmacodynamic data (i.e., there are no randomized efficacy or safety trial data assessing clinical outcomes for stroke thromboprophylaxis in atrial fibrillation at chronic kidney disease [CKD] G4\u2013G5). a Cockcroft-Gault estimated creatinine clearance (eCrCl). b Apixaban\npatients with moderate renal impairment. Circ J. 2013;77:632\u2013638 720; Stanifer J, Pokorney S, Chertow G, et al. Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease. Circulation. 2020;141:1384\u20131392 721; Hijazi Z, Alexander JH, Li Z, et al. Apixaban or\nConsiderations for implementation. A decision not to anticoagulate for thromboembolic prophylaxis due to low risk would ideally be re-evaluated at each consultation and at least every 6 months. When using antithrombotic therapy in people with CKD, it is prudent to treat modifiable risk factors for\n43. Su X, Yan B, Wang L, et al. Oral anticoagulant agents in patients with atrial fibrillation and CKD: a systematic review and pairwise network meta-analysis. Am J Kidney Dis. 2021;78:678\u2013689.e1.\nWe recommend use of non\u2013vitamin K antagonist oral anticoagulants (NOACs) in preference to vitamin K antagonists (e.g., warfarin) for thromboprophylaxis in atrial \ufb01brillation in people with CKD G1\u2013G4 (1C).\nWe recommend use of non\u2013vitamin K antagonist oral anticoagulants (NOACs) in preference to vitamin K antagonists (e.g., warfarin) for thromboprophylaxis in atrial fibrillation in people with CKD G1\u2013G4 (1C).\nRecent cardiology guidelines recommend a risk factor\u2013based approach to stroke thromboprophylaxis decisions in atrial fibrillation using the Congestive heart failure, Hypertension, Age $75 (doubled), Diabetes, Stroke (doubled), Vascular disease, Age 65 to 74, and Sex category (female) (CHA 2DS -2\nFigure 40 | Strategies for the diagnosis and management of atrial fibrillation. *Consider dose adjustments necessary in people with chronic kidney disease (CKD). \u2020The following has been recommended as a standard package for diagnostic evaluation of new atrial fibrillation: (i) a 12-lead",
    "ground_truth_context": "Figure S12. PRISMA diagram for the clinical question \u201cWhat are the effects of NOACs with or without warfarin compared to placebo or warfarin alone among people with CKD and atrial fibrillation in terms of stroke and bleeding risks?\u201d",
    "model_answer": "C",
    "model_answer_idx": 3,
    "correct_answer_text": "Use a NOAC, but monitor for bleeding risks.",
    "correct_answer_idx": 2,
    "model_reasoning": "The guidelines recommend the use of non-vitamin K antagonist oral anticoagulants (NOACs) for thromboprophylaxis in patients with atrial fibrillation and chronic kidney disease (CKD) G1\u2013G4. In this case, the 65-year-old male has CKD, and while NOACs are preferred over warfarin, it is crucial to monitor for bleeding risks due to the patient's renal impairment. Warfarin is not recommended because it requires close monitoring of INR and has challenges related to efficacy in this population. Avoiding anticoagulation altogether is not appropriate given the patient's history of atrial fibrillation, which increases the risk of stroke. Therefore, the most appropriate approach is to use a NOAC while being vigilant about potential bleeding risks associated with its use in the context of CKD.",
    "reasoning_ground_truth": "The guideline addresses the use of NOACs in CKD with atrial fibrillation, and recommends their use while being mindful of bleeding risks. Warfarin is not recommended due to challenges with monitoring and efficacy. Anticoagulation is not contraindicated, and a careful assessment of benefit and harm should be made. NOAC use in CKD requires assessment of dose and kidney function.",
    "is_correct": false
  },
  {
    "question": "A 75 year old male is admitted to the hospital with decompensated heart failure. He is treated with IV furosemide but remains volume overloaded. What type of fluid should be used for volume resuscitation in this case?",
    "context": "or renal failure), then it is highly likely that they are volume depleted and will respond to an appropriate fluid challenge. There is little evidence supporting the use of any specific fluid for volume loading in ALF. However, general critical care literature [130\u2013133]. The choice should be guided\n- Most patients are volume depleted at presentation and require crystalloid volume resuscitation (evidence level II-1, grade of recommendation 1).\nresuscitation needs to be assessed individually. In patients with elevated right sided cardiac pressures and ascites, further fluid therapy is likely to have limited or minimal improve venous return and improve cardiac index [148].\nFollowing adequate volume loading, persistent hypotension requires treatment with vasopressors. Given the usual clinical picture in ALF of an elevated cardiac output and decreased vascular tone, norepinephrine, at a starting dose of 0.05 lg/kg/min. Additional low dose vasopressin (1\u20132 units/hour),\nway to the setting of a hyperdynamic circulation [139]. ScvO2 will be elevated even if the patient is volume depleted and fluid responsive [140]. The purpose of bolus fluid therapy is to increase stroke volume and subsequently, cardiac output. Assessment of an appropriate increase in cardiac output",
    "ground_truth_context": "If used in this context, albumin should be viewed more as a drug, than as a resuscitative solution.",
    "model_answer": "C",
    "model_answer_idx": 3,
    "correct_answer_text": "Albumin",
    "correct_answer_idx": 2,
    "model_reasoning": "In the context of a 75-year-old male with decompensated heart failure who remains volume overloaded despite treatment with IV furosemide, the choice of fluid for volume resuscitation is critical. While 0.9% Normal Saline and Lactated Ringer's Solution are commonly used for volume resuscitation, they may not be the best options for patients with significant hypoalbuminemia or those who are volume overloaded. \n\nAlbumin, in this case, is considered more than just a resuscitative solution; it acts as a colloid that can help to expand intravascular volume and improve oncotic pressure. This is particularly important in patients who may have low serum albumin levels due to chronic conditions such as heart failure. Although the patient does not have liver failure, the principles of using albumin as a volume resuscitation agent apply similarly in cases of heart failure where fluid management is challenging.\n\nTherefore, given the patient's condition and the need for effective volume resuscitation, albumin is the most appropriate choice among the options provided.",
    "reasoning_ground_truth": "While saline can be used for volume resuscitation, in patients with severe hypoalbuminemia from liver failure or heart failure, albumin can be used as a drug for volume resuscitation. Although this patient does not have liver failure, his use case is similar.",
    "is_correct": false
  },
  {
    "question": "A 50 year old male is admitted for a planned coronary artery bypass graft (CABG) surgery. He is currently on dual antiplatelet therapy (DAPT).  What is the recommendation for continuation of DAPT?",
    "context": "Issues related to the timing of discontinuation of DAPT before CABG are beyond the scope of this update but are addressed in the 2011 CABG guideline (10). Figure 3 summarizes recommendations for the management and duration of P2Y12 inhibitor therapy in patients undergoing CABG.\n|---|---|---|---|\n|In patients treated with DAPT after coronary stent implantation who subsequently undergo CABG, P2Y12 inhibitor therapy should be resumed postoperatively so that DAPT continues until the recommended duration of therapy is completed.|I|C-EO| |\nThe scope of this focused update is limited to addressing recommendations on duration of dual antiplatelet therapy (DAPT) (aspirin plus a P2Y12 inhibitor) in patients with coronary artery disease (CAD). Recommendations considered are those in 6 guidelines: \u201c2011 ACCF/AHA/SCAI Guideline for\n|I|C-LD|In patients with ACS (NSTE-ACS or STEMI) being treated with DAPT who undergo CABG, P2Y12 inhibitor therapy should be resumed after CABG to complete 12 months of DAPT therapy after ACS (52\u201354,118\u2013120).| |\nIntensification of antiplatelet therapy, with the addition of a P2Y12 inhibitor to aspirin monotherapy, as well as prolongation of DAPT, necessitates a fundamental tradeoff between decreasing ischemic risk and increasing bleeding risk. Decisions about treatment with and duration of DAPT require a\n|COR|LOE|RECOMMENDATION|\n|---|---|---|\n|I|C-LD|In patients with ACS being treated with DAPT who undergo CABG, P2Y12 inhibitor therapy should be resumed after CABG to complete 12 months of DAPT therapy after ACS (52\u201354,118\u2013120).|",
    "ground_truth_context": "Issues and recommendations with regard to P2Y12 inhibitor \u201cpre-treatment,\u201d \u201cpreloading,\u201d and loading are beyond the scope of this document but are addressed in other guidelines.",
    "model_answer": "A",
    "model_answer_idx": 1,
    "correct_answer_text": "DAPT should be stopped at least 5 days prior to surgery.",
    "correct_answer_idx": 0,
    "model_reasoning": "The recommendation for the management of dual antiplatelet therapy (DAPT) prior to coronary artery bypass graft (CABG) surgery generally advises that DAPT should be stopped at least 5 days before the procedure. This is to minimize the risk of excessive bleeding during surgery, which is a significant concern when patients are on antiplatelet medications. While the specific context provided does not detail the exact timing for discontinuation, it aligns with the general consensus in clinical practice and guidelines for elective surgeries, including CABG. The other options either suggest a shorter duration of stopping DAPT or continuing it through the surgery, which are not consistent with the standard recommendations aimed at ensuring patient safety during surgical procedures.",
    "reasoning_ground_truth": "While the guidelines focus on duration of DAPT, the general consensus for elective surgeries including CABG is to stop DAPT at least 5 days prior to surgery, with some exceptions made for very high risk patients.",
    "is_correct": false
  },
  {
    "question": "A 60-year-old male with a history of hypertension presents with a persistent cough, fever, and shortness of breath. A chest X-ray reveals a right lower lobe infiltrate. Initial blood cultures are negative. What is the most appropriate next step in his management?",
    "context": "and symptoms of pneumonia with radiographic confirmation) to completion of antimicrobial therapy and follow-up chest imaging.\nIn Adults with CAP Who Are Improving, Should Follow-up Chest Imaging Be Obtained?\ndeterioration, aspiration and poor compliance. Regular chest physiotherapy should be carried out and ventilator associated pneumonia avoided (evidence level III, grade of recommendation 1).\nprompt assessment for a pathogen resistant to the current therapy and/or complications of pneumonia (e.g., empyema or lung abscess) or for an alternative source of infection and/or inflammatory response (208, 209). When assessment of clinical stability has been introduced into clinical practice,\nswab is positive, coverage for MRSA pneumonia should generally be initiated, but blood and sputum cultures should be sent and therapy deescalated if cultures are negative.\nLonger courses of antibiotic therapy are recommended for 1) pneumonia e59\nIn adults with CAP whose symptoms have resolved within 5 to 7 days, we suggest not routinely obtaining follow-up chest imaging (conditional recommendation, low quality of evidence).\nradiographically confirmed CAP, b-lactam plus macrolide combination therapy, or fluoroquinolone monotherapy were generally associated with lower mortality than b-lactam monotherapy (105). Therefore, the panel recommends a b-lactam (ampicillin plus sulbactam, cefotaxime, ceftaroline, or ceftriaxone)",
    "ground_truth_context": "our recommendations are to initially treat empirically for possible bacterial infection or coinfection. Routinely obtaining blood cultures may generate false-positive results that lead to unnecessary antibiotic use and increased length of stay.",
    "model_answer": "A",
    "model_answer_idx": 1,
    "correct_answer_text": "Start empiric antibiotic therapy for community-acquired pneumonia (CAP)",
    "correct_answer_idx": 0,
    "model_reasoning": "The patient's presentation of a persistent cough, fever, and shortness of breath, along with the chest X-ray findings of a right lower lobe infiltrate, is highly suggestive of community-acquired pneumonia (CAP). According to the guidelines, the most appropriate next step in management for suspected CAP is to initiate empiric antibiotic therapy. This is crucial to address the potential bacterial infection or coinfection promptly, as delaying treatment could worsen the patient's condition.\n\nWhile blood cultures are typically recommended, they should not delay the initiation of antibiotics, especially since the initial blood cultures in this case are negative. The other options provided are not appropriate first-line steps for managing a typical case of CAP. Prescribing cough suppressants would not address the underlying infection, performing a bronchoscopy is more invasive and not necessary at this stage, and ordering a CT scan to rule out pulmonary embolism is not indicated given the clear signs of pneumonia. Therefore, starting empiric antibiotic therapy is the best course of action.",
    "reasoning_ground_truth": "The patient's symptoms and chest X-ray findings are consistent with CAP. The guidelines recommend initiating **empiric antibiotic therapy** for possible bacterial infection or coinfection. Although blood cultures are recommended, they should not delay the start of antibiotic treatment. The other options are not the first-line steps for a typical CAP case.",
    "is_correct": false
  },
  {
    "question": "A 72-year-old female with known chronic kidney disease (CKD) and type 2 diabetes is admitted for a urinary tract infection. Her estimated glomerular filtration rate (eGFR) based on serum creatinine (SCr) is 35 mL/min/1.73 m\u00b2. What is the most appropriate approach for medication dosing?",
    "context": "Practice Point 4.1.2: Monitor eGFR, electrolytes, and therapeutic medication levels, when indicated, in people with CKD receiving medications with narrow therapeutic windows, potential adverse effects, or nephrotoxicity, both in outpatient practice and in hospital settings.\nMonitor eGFR, electrolytes, and therapeutic medication levels, when indicated, in people with CKD receiving medications with narrow therapeutic windows, potential adverse effects, or nephrotoxicity, both in outpatient practice and in hospital settings. Ensuring a safe use of medication requires\nMany medications and/or their active metabolites are excreted by the kidneys. Failure to properly account for the effect of GFR when designing appropriate drug-dosing regimens can predispose a person to treatment failure or adverse events. 725, 728 Although guidelines for adjustment of the dosing\nPractice Point 3.6.5: Consider reducing the dose or discontinuing ACEi or ARB in the setting of either symptomatic hypotension or uncontrolled hyperkalemia despite medical treatment, or to reduce uremic symptoms while treating kidney failure (estimated glomerular filtration rate [eGFR] &lt;15\n36. Chertow GM, Lee J, Kuperman GJ, et al. Guided medication dosing for inpatients with renal insufficiency. JAMA. 2001;286:2839\u20132844.\n37. Erler A, Beyer M, Petersen JJ, et al. How to improve drug dosing for patients with renal impairment in primary care\u2014a cluster-randomized controlled trial. BMC Fam Pract. 2012;13:91.\nIn particular, can lower or higher doses be used in different settings (perhaps dependent on baseline risk), and should dosing be adjusted in obese patients, underweight patients, and patients with renal disease?\nRecommendation 3.7.3: We suggest treating adults with eGFR 20 to 45 ml/min per 1.73 m2 with urine ACR <200 mg/g (<20 mg/mmol) with an SGLT2i (2B).\nWe suggest treating adults with eGFR 20 to 45 ml/min per 1.73 m2 with urine ACR <200 mg/g (<20 mg/mmol) with an SGLT2i (2B).\nPractice Point 4.2.1: Consider GFR when dosing medications cleared by the kidneys.  \nPractice Point 4.2.2: For most people and clinical settings, validated eGFR equations using SCr are appropriate for drug dosing.\nPractice Point 3.7.1: Once an SGLT2i is initiated, it is reasonable to continue an SGLT2i even if the eGFR falls below 20 ml/min per 1.73 m\u00b2, unless it is not tolerated or KRT is initiated.  \nRecommendation 3.7.2: We recommend treating adults with CKD with an SGLT2i for the following (1A):",
    "ground_truth_context": "Where more accuracy is required for drug-related decision-making (e.g., dosing due to narrow therapeutic or toxic range), drug toxicity, or clinical situations where eGFRcr estimates may be unreliable, use of equations that combine both creatinine and cystatin C, or measured GFR may be indicated.",
    "model_answer": "B",
    "model_answer_idx": 2,
    "correct_answer_text": "Use equations that combine both creatinine and cystatin C for drug dosing.",
    "correct_answer_idx": 1,
    "model_reasoning": "In the context of the patient's chronic kidney disease (CKD) and the need for accurate medication dosing, it is crucial to consider the limitations of using serum creatinine (SCr) alone for estimating glomerular filtration rate (eGFR). While validated eGFR equations using SCr are generally appropriate for drug dosing, they may not provide sufficient accuracy in certain clinical situations, particularly when dealing with medications that have a narrow therapeutic window or potential toxicity. \n\nIn this case, the patient has an eGFR of 35 mL/min/1.73 m\u00b2, which indicates moderate renal impairment. To ensure safe and effective medication dosing, especially in the presence of CKD and the potential for drug-related complications, it is advisable to use equations that combine both creatinine and cystatin C. These combined equations can provide a more accurate assessment of kidney function, which is essential for making informed decisions about medication dosing.\n\nOptions A, C, and D are not appropriate in this scenario. Option A relies solely on SCr, which may not be sufficient for accurate dosing. Option C (immediate initiation of dialysis) is not warranted based solely on the eGFR value without further clinical indication. Option D (discontinuing all medications) is overly cautious and may not be necessary, as appropriate adjustments can be made based on a more accurate assessment of kidney function. Therefore, option B is the most appropriate approach for medication dosing in this patient.",
    "reasoning_ground_truth": "For most people, validated eGFR equations using SCr are appropriate for drug dosing. However, when **more accuracy** is needed, such as with a narrow therapeutic range, drug toxicity, or when eGFR estimates may be unreliable, equations that combine both creatinine and cystatin C, or measured GFR may be indicated.",
    "is_correct": false
  },
  {
    "question": "A 55-year-old male presents with a first-time seizure lasting 7 minutes. He has no history of epilepsy. Intravenous (IV) access is difficult to obtain. What is the preferred initial pharmacologic treatment?",
    "context": "The following conclusions were drawn. In adults, IM midazolam, IV lorazepam, IV diazepam (with or without phenytoin), and IV phenobarbital are established as efficacious at stopping seizures lasting at least 5 minutes (level A). Intramuscular midazolam has superior effectiveness compared with IV\nThe algorithm starts with a stabilization phase (0\u20135 minutes), which includes standard initial first aid for seizures. The initial therapy phase should begin when the seizure duration reaches 5 minutes and should conclude by the 20-minute mark when response (or lack of response) to initial therapy\nThe second-therapy phase should begin when the seizure duration reaches 20 minutes and should conclude by the 40-minute mark when response (or lack of response) to the second therapy should be apparent. Reasonable options include fosphenytoin (level U), valproic acid (level B, one class II study)\nreceive a second dose of medication if the seizures continued after 10 minutes. For all patients, phenytoin was given after 30 minutes. A total of 70 patients were randomized to either lorazepam (n = 37) or diazepam (n = 33) (25). Lorazepam was successful for 78% of subjects after one dose and 89%\nor longer, or two or more GTC seizures without full recovery of consciousness. A treatment was successful if the status epilepticus stopped within 20 minutes after infusion started with no recurrence prior to 60 minutes. Overall, 570 patients were randomized to either lorazepam (n = 146), diazepam\nNine RCTs (three class I [22\u201324], one class II [25], and five class III [26\u201330]) addressed the efficacy of initial therapy. The 1998 Veteran\u2019s Affairs status epilepticus study was a multi-center randomized comparison of four different IV treatments: lorazepam (0.1 mg/kg), diazepam (0.15 mg/kg)\nConvulsive status epilepticus treated with placebo indicating that respiratory problems are an important consequence of untreated convulsive status epilepticus (Level A). When both are available, fosphenytoin is preferred over phenytoin based on tolerability but phenytoin is an acceptable\nmg/kg), diazepam (0.15 mg/kg) followed by phenytoin (18 mg/kg), phenobarbital (18 mg/kg), and phenytoin alone (18 mg/kg) in adults with either overt or subtle status epilepticus (22). Overt status epilepticus was defined as a continuous GTC seizure lasting 10 minutes or longer, or two or more GTC",
    "ground_truth_context": "In adults with convulsive status epilepticus, intramuscular midazolam, intravenous lorazepam, intravenous diazepam and intravenous phenobarbital are established as efficacious as initial therapy (Level A). Intra-muscular midazolam has superior effectiveness compared to intravenous lorazepam in adults with convulsive status epilepticus without established intravenous access (Level A).",
    "model_answer": "A",
    "model_answer_idx": 1,
    "correct_answer_text": "Intramuscular midazolam",
    "correct_answer_idx": 0,
    "model_reasoning": "In the context of a 55-year-old male presenting with a first-time seizure lasting 7 minutes and having difficulty obtaining intravenous (IV) access, the preferred initial pharmacologic treatment is intramuscular midazolam. The reasoning behind this choice is based on the established efficacy of intramuscular midazolam in adults with convulsive status epilepticus, particularly when IV access is challenging. \n\nWhile IV lorazepam is a first-line treatment for status epilepticus, it requires IV access, which is not feasible in this scenario. Intramuscular midazolam has been shown to have superior effectiveness compared to IV lorazepam in situations where IV access cannot be established. Although rectal diazepam is a reasonable alternative, midazolam is preferred due to its better effectiveness in this specific situation. Therefore, intramuscular midazolam is the most appropriate choice for initial treatment in this case.",
    "reasoning_ground_truth": "For patients with convulsive status epilepticus where **IV access is difficult**, intramuscular midazolam is superior to intravenous lorazepam. IV lorazepam is a first line treatment for status epilepticus, but if an IV line cannot be established, IM midazolam is prefered. Rectal diazepam is a reasonable alternative, but midazolam has better effectiveness when IV access is not established.",
    "is_correct": false
  },
  {
    "question": "A 48-year-old woman with a history of heavy alcohol use presents with jaundice, ascites, and confusion. She has been diagnosed with alcoholic hepatitis. What is the initial nutritional recommendation?",
    "context": "In patients with severe alcoholic hepatitis, oral intake is consistently reduced [110,111,142,181]. When the treatments are consistent in the groups, supplemental nutrition does improve infection and acute mortality, specifically in hospital deaths over ad lib oral dietary intake [186e188]. Enteral\nin patients with NAFLD [288]. These findings were not included in the AASLD/AG [120] and EASL/EASD/EASO [119] guidelines recommending only to abstain from heavy amounts of alcohol. Until evidence from intervention studies is available it seems unjustified to suggest a potential health benefit from\nTake an alcohol history to rule out alcohol-related liver disease. See also NICE's guideline on cirrhosis.\n1.2.16 Explain to people with NAFLD who drink alcohol the importance of staying within the national recommended limits for alcohol consumption.\n44. Nasrallah SM, Galambos JT. Aminoacid therapy of alcoholic hepatitis. Lancet 1980;2(8207):1276e7.\n45. Koretz RL, Avenell A, Lipman TO. Nutritional support for liver disease. Cochrane Database Syst Rev 2012;(5), Cd008344.\nA total of 85 recommendations were made for the nutritional and metabolic management of patients with acute liver failure, severe alcoholic steatohepatitis, non-alcoholic fatty liver disease, liver cirrhosis, liver surgery and transplantation as well as nutrition associated liver injury distinct\n40. Mendenhall C, Bongiovanni G, Goldberg S, Miller B, Moore J, Rouster S, et al. VA cooperative study on alcoholic hepatitis. III: changes in protein-calorie malnutrition associated with 30 days of hospitalization with and without enteral nutritional therapy. J Parenter Enteral Nutr\nintake [186e188]. Enteral or supplemental feeding has been evaluated in severe alcoholic hepatitis, but no mortality benefit has been consistently reported. In the VA studies, a survival advantage to supplemental nutrition was reported in patients with malnutrition. In a meta-analysis of 13\nadequate calorie and protein intake by supplementation. Whether alcoholic hepatitis is a state of accelerated starvation akin to cirrhosis has not been directly reported, metabolomic studies and metabolic cart studies suggest hyper-metabolism, accelerated lipolysis and accelerated starvation",
    "ground_truth_context": "A total of 85 recommendations were made for the nutritional and metabolic management of patients with acute liver failure, severe alcoholic steatohepatitis, non-alcoholic fatty liver disease, liver cirrhosis, liver surgery and transplantation as well as nutrition associated liver injury",
    "model_answer": "C",
    "model_answer_idx": 3,
    "correct_answer_text": "Start enteral nutrition with a standard formula",
    "correct_answer_idx": 2,
    "model_reasoning": "The patient in question has been diagnosed with alcoholic hepatitis, which is a severe liver condition that often requires immediate nutritional management to support liver function and overall health. According to the context provided, enteral nutrition is recommended as a safe and effective method for delivering nutritional support to patients with liver disease. Starting enteral nutrition with a standard formula is crucial in this scenario, as it helps ensure adequate calorie and protein intake, which is essential for recovery and managing complications associated with liver disease.\n\nOptions A and D, which involve restricting fluid intake and delaying nutritional support, could potentially worsen the patient's condition and lead to further complications. Option B, initiating a high-protein, low-carbohydrate diet, is not specifically recommended in the context of severe alcoholic hepatitis without the support of enteral nutrition. Therefore, the most appropriate initial nutritional recommendation for this patient is to start enteral nutrition with a standard formula.",
    "reasoning_ground_truth": "The patient has signs of liver disease, which requires nutritional management. Based on the liver disease guideline, enteral nutrition should be started and is a safe route for delivery of nutritional support for patients with liver disease. Restricting fluids and or delaying nutrition may cause significant harm.",
    "is_correct": false
  },
  {
    "question": "A 50-year-old patient with a history of coronary artery disease underwent percutaneous coronary intervention (PCI) with drug-eluting stent placement. How long should dual antiplatelet therapy (DAPT) be continued?",
    "context": "recommended duration of P2Y12 inhibitor therapy (in addition to aspirin therapy). Figure 1 summarizes recommendations for duration of DAPT according to clinical status.\nThe scope of this focused update is limited to addressing recommendations on duration of dual antiplatelet therapy (DAPT) (aspirin plus a P2Y12 inhibitor) in patients with coronary artery disease (CAD). Recommendations considered are those in 6 guidelines: \u201c2011 ACCF/AHA/SCAI Guideline for\n|---|---|---|---|\n|In patients treated with DAPT after coronary stent implantation who subsequently undergo CABG, P2Y12 inhibitor therapy should be resumed postoperatively so that DAPT continues until the recommended duration of therapy is completed.|I|C-EO| |\nboth in those treated with revascularization (PCI or CABG) and in those treated with medical therapy alone (51,52). Available evidence from this trial, as well as from PLATO (53,71,72) and TRITON-TIMI 38 (54,55), supports DAPT duration of at least 12 months for patients with NSTE-ACS.\n|---|---|---|\n|I|A|In patients with STEMI treated with DAPT in conjunction with fibrinolytic therapy, P2Y12 inhibitor therapy (clopidogrel) should be continued for a minimum of 14 days (Level of Evidence: A) (140,142) and ideally at least 12 months (Level of Evidence: C-EO).|\n|IIb|ASR|In patients with ACS treated with coronary stent implantation who have tolerated DAPT without bleeding complication and who are not at high bleeding risk (e.g., prior bleeding on DAPT, coagulopathy, oral anticoagulant use) continuation of DAPT for longer than 12 months may be reasonable\n|I|C-LD|In patients with ACS (NSTE-ACS or STEMI) being treated with DAPT who undergo CABG, P2Y12 inhibitor therapy should be resumed after CABG to complete 12 months of DAPT therapy after ACS (52\u201354,118\u2013120).| |",
    "ground_truth_context": "Most contemporary studies of DAPT have compared either shorter (3 to 6 months) (17\u201321) or longer (18 to 48 months) (16,22\u201326) duration of therapy with 12 months of DAPT, which is the recom-mended or minimal duration of therapy for most patients in ACC/AHA (9,13,14) and European Society of Cardiology (31\u201333) guidelines published between 2011 and 2014.",
    "model_answer": "C",
    "model_answer_idx": 3,
    "correct_answer_text": "12 months",
    "correct_answer_idx": 2,
    "model_reasoning": "The recommended duration of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) with drug-eluting stent placement is typically 12 months. This recommendation is supported by various guidelines, including those from the ACC/AHA and the European Society of Cardiology, which indicate that 12 months is the standard or minimal duration of therapy for most patients. While some patients may require shorter or longer durations based on individual risk factors and clinical scenarios, the general consensus is that 12 months is the appropriate duration for optimal outcomes in patients with coronary artery disease who have undergone PCI. Therefore, option C (12 months) is the correct answer.",
    "reasoning_ground_truth": "For most patients, 12 months of DAPT is the recommended or minimal duration of therapy following PCI with drug-eluting stent placement. The duration can vary based on the patient profile, but 12 months is the standard recommendation.",
    "is_correct": false
  },
  {
    "question": "A 68-year-old male with a history of benign prostatic hyperplasia (BPH) and hypertension presents with new-onset fatigue, constipation, and dry skin. His TSH level is elevated, and free T4 level is low. What is the appropriate initial treatment?",
    "context": "Treatment based on individual factors for patients with TSH levels between the upper limit of a given laboratory\u2019s reference range and 10 mIU/L should be considered particularly if patients have symptoms suggestive of hypothyroidism, positive TPOAb or evidence of atherosclerotic cardiovascular\ntherapy (54,55) (see L-thyroxine treatment of hypothyroidism).\nPatients whose serum TSH levels exceed 10 mIU/L are at increased risk for heart failure and cardiovascular mortality, and should be considered for treatment with L-thyroxine. Grade B, BEL 1\nPatients with hypothyroidism should be treated with L-thyroxine monotherapy. Grade A, BEL 1  \nSee: L-thyroxine treatment of hypothyroidism\nwith L-thyroxine. This has been reported in 20% of those treated with thyroid hormone (12). The principal adverse consequences of subtle or frank overtreatment are cardiovascular (187-190), skeletal (191-194), and possibly affective disturbances (195-197). The elderly are particularly susceptible to\nSee: L-thyroxine treatment of hypothyroidism\nWhen initiating therapy in patients older than 50-60 years with overt hypothyroidism, without evidence of coronary heart disease, an L-thyroxine dose of 50 \u00b5g daily should be considered. Grade D, BEL 4  \nSee: L-thyroxine treatment of hypothyroidism\nthan younger patients, due to decreased lean body mass (152,153). Regardless of the degree of hypothyroidism, patients older than 50-60 years, without evidence of coronary heart disease (CHD) may be started on doses of 50 \u00b5g daily. Among those with known CHD, the usual starting dose is reduced to",
    "ground_truth_context": "The standard treatment is replacement with L-thyroxine which must be tailored to the individual patient.",
    "model_answer": "C",
    "model_answer_idx": 3,
    "correct_answer_text": "Levothyroxine (T4) monotherapy",
    "correct_answer_idx": 2,
    "model_reasoning": "The patient's symptoms of fatigue, constipation, and dry skin, along with elevated TSH and low free T4 levels, indicate primary hypothyroidism. According to the context provided, the standard treatment for hypothyroidism is L-thyroxine (T4) monotherapy. This is supported by the guideline stating that patients with hypothyroidism should be treated with L-thyroxine monotherapy (Grade A, BEL 1). \n\nLiothyronine (T3) monotherapy (Option A) is not recommended as a first-line treatment for hypothyroidism, and combination therapy with T4 and T3 (Option B) is generally not advised in most cases. Thyroid-stimulating hormone (TSH) injection therapy (Option D) is also not a standard treatment for hypothyroidism. Therefore, the most appropriate initial treatment for this patient is Levothyroxine (T4) monotherapy (Option C).",
    "reasoning_ground_truth": "The patient's symptoms and lab results are consistent with primary hypothyroidism. The standard treatment is replacement with L-thyroxine (T4). Combination therapy with T3 is not recommended in the majority of cases.",
    "is_correct": false
  },
  {
    "evaluation_metrics": {
      "accuracy": 0.0,
      "total": 39,
      "correct": 0,
      "confusion_matrix": {
        "Pred A": {
          "True A": 0,
          "True B": 0,
          "True C": 0,
          "True D": 0
        },
        "Pred B": {
          "True A": 12,
          "True B": 0,
          "True C": 0,
          "True D": 0
        },
        "Pred C": {
          "True A": 0,
          "True B": 18,
          "True C": 0,
          "True D": 0
        },
        "Pred D": {
          "True A": 0,
          "True B": 0,
          "True C": 1,
          "True D": 0
        }
      }
    }
  }
]